Table of Contents

A Letter from the CBA President

Dear CBA Members and Friends:

I am greatly honored to welcome all of you to our **21st Chinese Biopharmaceutical Association-USA (CBA) Annual Conference**. CBA collaborates with MedImmune to host its 21st annual conference on June 11, 2016 at the beautiful campus and the state-of-art conference facility of MedImmune, a member of the AstraZeneca group, and the largest biopharmaceutical company in Maryland.

It has been two tumultuous decades of growth for the CBA. Twenty years ago, we were a tiny group of young scientists, all with ties to China. But we had a big vision: to create a platform for collaboration in life sciences and the biopharmaceutical industry. Thanks to the dedication of our members, CBA has grown into a truly global organization with a strong and growing reputation. We have remained true to our founding mission, and this conference will serve to reinforce and extend the commitment of CBA to fostering greater global collaboration and new partnerships between China and USA in the biotech and pharmaceutical arenas.

It has been my honor to be the chair of the 2016 Conference Organization Committee. The theme of the 21st CBA annual **c**onference is "***Biopharm USA-China: Accelerating Global Development and Commercialization through Partnerships*"**. The theme has been carefully selected to address the critical importance of worldwide collaboration and partnership to capture the great opportunities for the advancement of innovative medicine and biopharmaceuticals in both USA and China.

We are very fortunate and honored to have more than 20 distinguished leaders in our Conference Program, including the CBA Brilliant Award Keynote Speeches and six sessions that bring together the elite minds from around the world to share their insights on the latest progress in global biopharmaceutical development. In fact, it is fair to say that this very distinguished group of research and business leaders has been in the forefront of global collaboration, especially in reaching out to the scientific and corporate community in China to assure that they are important players on this world stage. Indeed, this year's theme of global collaboration and partnership is exemplified by the recognition of two distinguished leaders, Dr. Bahija Jallal, EVP of AstraZeneca and Head of MedImmune, and Dr. Ge Li, CEO and Chairman of Board of Directors, WuXi AppTec, both representing two top global biopharmaceutical companies who are tirelessly fostering US-China global collaborations.

The conference provides a perfect venue for people from government, private agencies, biotech and pharmaceutical companies interested in policy issues, business development, and partnership in US and China.

One unique feature of this year's conference is the presence of delegations from some of China's leading high-tech companies and R&D centers. These include representatives from

China Pharmaceutical Technology Transfer Center (CPTTC), China Association for Pharmaceutical Enterprises Development, Peking & Tsinghua Venture Science and Technology Development Co., Ltd., Institute of Bio-medicine, Jinan University, Beijing Qihuang Medicine Clinical Research Center, Ch-gemstone Capital (Beijing) Corp, Sichuan Academy of Chinese Medicine Sciences, Shanghai Yeli Biotech Company and Changchun BCHT Biotechnology Co. Ltd. They are here seeking opportunities to forge new partnerships, establish new collaborations, and identify new research and investment opportunities. We encourage all attendees to take advantage of their presence this year to learn more about the exceptional R&D and investment resources each of them has to offer.

CBA has received very generous support from our sponsors this year, including NaiLii, MedImmune, WuXi AppTec, NovaVax, PharmEng Technology, Luye Pharma Group, Shanghai Furen Medicine R&D Co. Ltd., ArrayBridge, Millipore, Agilent, Ascentage, ChemPartner, Crown Bioscience Inc., DiscoverX, GeneScript, JSR Micro, Noegen Inc., OriGene, Promega, Sepax, Teruisi Pharmaceuticals, Tianjin CanSino Biotechnology Inc., Tianjin Jun Yao Trading, Waters, National Foundation of Cancer Research (US) and US Maryland State Government and Montgomery County Government. On behalf of the CBA, I would like to sincerely thank all of our sponsors for their strong commitment and contributions to the success of this conference.

As the chair of this year's Conference Organizing Committee, I must express my profound gratitude to all of the committee members and many CBA members and volunteers who have worked so diligently to organize all the fine details and assure that each of you has an outstanding experience at this year's event. Thank you all for your support. I am most grateful for your commitment and dedication to this year's conference.

Sincerely,

Xu-Rong Jiang, M.D., Ph.D.

Biopharm US-China: Accelerating Global Development and Commercialization through Partnerships

Saturday, June 11, 2016
Wayne T. Hockmeyer Auditorium
MedImmune, A Member of the AstraZeneca Group
1 MedImmune Way, Gaithersburg, MD 20878

Conference Program

7:30 AM – 8:30 AM **Registration and Continental Breakfast; Exhibition Booth Setup**

8:30 AM – 8:35 AM **Welcome to the 21st CBA Annual Conference**
Xu-Rong Jiang, M.D., Ph.D., President-elect of CBA

8:35 AM – 8:45 AM **Opening Remarks**
Minister Kexin Li, Embassy of the People's Republic of China in the USA

8:45 AM – 8:55 AM **Opening Remarks**
Mr. Luis Borunda, Deputy Secretary of the State of Maryland

8:55 AM – 9:00 AM **Introduction of the CBA Brilliant Achievement Awardees**

Shou-Bai Chao, Ph.D., President of CBA

9:00 AM – 9:30 AM **Brilliant Achievement Award Presentations**

A Dream, a Platform, and a Transformation
Ge Li, Ph.D., CEO and Chairman of Board of Directors, WuXi AppTec

9:30 AM–10:00 AM Bahija Jallal, Ph.D., EVP of AstraZeneca, Head of MedImmune, a Member of the AstraZeneca Group

10:00 AM–10:20 AM **Break and Refreshments**

10:20 AM–11:35 AM **Session 1: Regulatory Challenges and Opportunities in China and US**

Session Chairs: **Dan Zhang**, M.D., President & CEO, Fountain Medical Development Ltd, and **Qiao Bobo**, Ph.D., Review and Inspection Officer, FDA

10:20 AM–10:40 AM **New Policies and New Regulatory Strategy in China**

Yi Feng, Ph.D., former Assistant to the Director-General of the CDE of CFDA

10:40 AM –11:00 AM **Regulatory Challenges and Opportunities for Companion Diagnostics**
Yun-Fu Hu, Ph.D., Associate Director, Division of Immunology and Hematology Devices, Office of In Vitro Diagnostic Device Evaluation and Safety, CDRH, FDA

11:00 AM–11:20 AM **Current Challenges in the Regulatory Landscape for US and China**
John Finkbohner, Ph.D., Senior Director, US RA, MedImmune

11:20 AM–11:35 AM **Session 1 Panel Discussion**
Panelists: Yi Feng, Yun-Fu Hu, John Finkbohner, Jinjie Hu

11:35 AM–12:30 PM **Session 2: Immune-oncology and Cell Therapy**

Session Chairs: **Yingxian Xiao**, Ph.D., President & CEO, Potomac Pharmaceuticals, Inc., and **Yuling Li**, Ph.D., Scientific Director, MedImmune

11:35 AM–11:55 AM **The Power of Combinations in Immuno-oncology**
Tony Ho, M.D., VP of Immuno-oncology, AstraZeneca

11:55 AM–12:15 PM **Facing Future Challenges—From Conception to Realization, a Development Platform at China's Bantang Biopharmaceuticals**
Wenbo Cao, Ph.D., General Manager, Sinobioway

12:15 PM –12:30 PM **Session 2 Panel Discussion**

Panelists: Tony Ho, Wenbo Cao, Linda Liu

12:30 PM –1:30 PM **Luncheon & Sponsor Presentations**

Session Chairs: **Min Zhu**, Ph.D., Principal Scientist, MedImmune, and **Kun Yao**, Ph.D., Director, AstraZeneca

12:40 PM – 1:00 PM **Market Trends for Consultants within Pharmaceutical Industries**
Rav Mahal, Managing Consultant at PharmEng Technology

1:00 PM – 1:15 PM **MilliporeSigma, A business of Merck KGaA**
Sylvia Mannino, Account Manager, Millipore

1:15 PM – 1:25 PM **Talent Recruitment at Luye Pharma**
Xiufang Zhang, HR Director, Luye Pharma Group

Afternoon Sessions

1:30 PM – 2:45 PM **Session 3**: Global Collaboration

Session Chairs: **Gayatri Varma**, Ph.D., Director of Partnerships, MedImmune, and **Ziping Wei**, Ph.D., Executive Director, Novavax, Inc.

1:30 PM – 1:50 PM **Collaborations and Partnerships at MedImmune**
Gayatri Varma**,** Ph.D., Director, Partnerships & Collaborations, MedImmune

1:50 PM – 2:10 PM **Development Trend and Model Innovation: Innovative Drug Internalization in China**
Guozhong Rui, Ph.D., Director, China Pharmaceutical Technology Transfer Center (CPTTC)

2:10 PM – 2:30 PM **Develop and Manufacture Global Quality Biopharmaceuticals in China**
Youling Wu, Ph.D., CEO, Teruisi Pharmaceuticals

2:30 PM – 2:45 PM **Session 3 Panel Discussion**

2:45 PM – 3:05 PM **Break and Refreshments**

3:05 PM – 4:20 PM **Session 4: Biomarkers, Translational Research and Precision Medicine**

Session Chairs: **Richard Zhao**, Ph.D., Professor, University of Maryland School of Medicine, and **Zhifeng Long,** Ph.D., President, Personal Diagnostix

3:05 PM – 3:25 PM **Baseline for Health**
Guo-Liang Yu, Ph.D., Chairman, Quantum Health Corporation

3:25 PM – 3:45 PM **Optimization of Next Generation Diagnostic Services for Pharmaceutical Development Programs**
Arejas Uzgiris, Ph.D., Senior Director of R&D, Siemens Healthcare for Companion Diagnostics and Strategic Biomarkers

3:45 PM – 4:05 PM **Transforming Precision Medicine: Opportunities and Challenges in Decoding the Real Genome**
Wei Zhou, Ph.D., CEO of Centrillion

4:05 PM – 4:20 PM **Session 4 Panel Discussion**

4:20 PM – 5:00 PM **Session 5**: **What Scientists and Entrepreneurs in US Should Know**

Session Chairs: **Ching-Jey George Chang**, Ph.D., Chair, ASQ509 Biomed/Biotech Special Interest Group, **Steve Chen**, J.D., Ph.D., Patent Counsel, DSM Nutritional Products LLC.

4:20 PM – 4:45 PM **Trade Secrets and Economic Espionage: Legal Risks in Advancing Technology between the U.S. and China**
Jeremy S. Wu, Committee of 100

4:45 PM – 5:00 PM **Session 5 Panel Discussion**
Panelists: Jeremy S. Wu, Lin Sun-Hoffman, Steve Chen

5:00 PM – 6:00 PM **Session 6 CBA-SCBA Joint Session - Cancer Therapeutics**

Session Chairs: **Li Yang**, Ph.D., Senior Investigator & Head, Tumor Microenvironment Section, Laboratory of Cancer Biology and Genetics, NCI, and **Mitchell Ho,** Ph.D., Senior Investigator, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI

5:00 PM – 5:15 PM **Targeting Myeloid TGF-beta Signaling in Cancer Metastasis**
Li Yang, Ph.D., Senior Investigator & Head, Tumor Microenvironment Section, Laboratory of Cancer Biology and Genetics, NCI

5:15 PM – 5:30 PM **Rationalize Target Combination in Cancer Cells**
Ji Luo Ph.D., Head, Cancer Systems Biology Section, Laboratory of Cancer Biology and Genetics (LCBG), NCI

5:30 PM – 5:45 PM **Novel Antibodies Target Cancer Signaling**
Mitchell Ho, Ph.D., Senior Investigator, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI

5:45 PM – 6:00 PM **Session 6 Panel Discussion**

6:00 PM **Closure of Exhibition**

6:15 PM- **Evening Reception**

21st CBA Annual Conference Reception and Dinner
第 21 届 CBA 年会招待酒会和晚宴

MedImmune Cafeteria, MedImmune
1 MedImmune Way，Gaithersburg, MD 20878

Open Bar Reception (6:15 PM – 7:00 PM)

Evening Session and Dinner (6:30 PM – 8:40 PM)

Masters of Ceremony: Shou-Bai-Chao, Ph.D. and Xu-Rong Jiang, M.D., Ph.D.

7:00 PM – 7:10 PM	**Opening Remarks by Masters of Ceremony**
7:10 PM – 7:30 PM	**Made in China in 2025** **Mr. Xianshao Xiang**, CEO, Shanghai Naili Biochemistry Equipment Co., Ltd., Shanghai Naili Fluid Equipment Co., Ltd.
7:30 PM – 7:45 PM	**Entertainment & Performance**
7:45 PM – 8:00 PM	**State of the CBA, Shou-Bai Chao, Ph.D.,** CBA President (2015- 2016)
8:00 PM – 8:10 PM	**2016 CBA Outstanding Service Award Presentation:** **Richard Zhao, Ph.D.,** CBA President (2012-2013)
8:10 PM – 8:20 PM	**2016 CBA President-Elect Election Announcement**
8:20 PM – 8:30 PM	**Concluding Remarks** **Xu-Rong Jiang, M.D., Ph.D.,** CBA President (2016 - 2017)

CBA Would Like to Thank the Following Sponsors for Their Generous Support:

Special Sponsor

上海耐利生化设备有限公司

Shanghai Naili Biochemistry Equipment Co., Ltd.

地址:上海松江区富永路 758 号 邮编:201600

758 Fuyong Road Songjiang District

Shanghai 201600P.R.China

Tel: +86 21 3352 1111 ext. 810

Fax: +86 21 3352 1180

Tel: +86 21 3352 1182

E-mail: xxs@NaiLii.com

http:www.NaiLii.com

Platinum Sponsors

Novavax, Inc.

20 Firstfield Road,

Gaithersburg, MD 20878

www.novavax.com

Contact: Russell P. "Rip" Wilson, SVP, Business Dev

Office phone: 240-268-2000

Investor & Media Relations:ir@novavax.com

Employment Opportunities:hr@novavax.com

Business Development: busdev@novavax.com

PharmEng Technology

23 Lesmill Road, Suite 410

Toronto, ON, M3B 3P6

Contact: Rav Mahal

Managing Consultant

Tel: (416) 303-3902

http://www.pharmeng.com/

WuXi Biologics

6 Montgomery Vlg Ave Ste 200,

Gaithersburg , MD 20879

Contact: Haodi Dong, MS MBA

Technical Director, Business Development

North America East Coast and Europe

mobile: +1 508.361.2898
Learn more @ www.wuxibiologics.com
Follow us @ www.linkedin.com/company/wuxi-biologics

MedImmune
One MedImmune Way
Gaithersburg, MD 20878
Contact: Tracy Rossin
Director, Corporate Public Relations, MedImmune
Tel: 301-398-1468
rossint@medimmune.com
twitter: @MedImmune
www.medimmune.com

Gold Sponsors

Millipore
EMD Millipore Corp
900 Middlesex Turnpike
Billerica, MA 01821 | USA
Contact: Sylvia Mannino
Account Manager Consultant, Pharma Processing
Tel: 443 244 5104
sylvia.mannino@emdmillipore.com
www.emdmillipore.com

ArrayBridge. Inc,
4320 Forest Park Ave, Suite 303.
St. Louis, MO 63108
Contact: Xing Wang
Tel: 636-284-4212
http://stores.arraybridge.com/

上海辅仁医药研发
Shanghai Furen Medicine R&D Co., Ltd
797 Puxing Road, Minhang District, Shanghai
Tel: 86-21-3473-0109
Fax: 86-21-3473-0110
info@shfrmrd.com
www.shfrmrd.com

Luye
绿叶制药集团
烟台市莱山区宝源路 9 号
Contact:张秀芳
Tel:86-0535-3808593
Fax: 86-0353-6717718
Email: zhangxiufang@luye.cn
www.luye.cn

Silver Sponsors

Maryland Department of Commerce
Office of International Investment & Trade
401 East Pratt Street, 7th Floor
Baltimore, MD 21202
Contact: Bradley Gillenwater
East Asia Regional Manager
Tel: 1-410-767-0688 | F 1-410-333-4302
commerce.maryland.gov

Agilent Technologies, Inc.
5301 Stevens Creek Blvd
Santa Clara, CA 95051
Contact: Susan Soileau, Account Manager
Tel: 302-636-3995/ Fax : 302-633-8953
Email: susan_soileau@agilent.com
www.agilent.com

Crown Biosciences
3375 Scott Blvd., Suite 108,
Santa Clara, ca 95054, USA
Contact: Guoliang Yu
Tel: 1-855-826-6968 (USA)
86-1069719900 (Beijing)
E-mail: guoliang.yu@gmail.com
www.crownbio.com

Waters Corporation
34 Maple Street
Milford, MA 01757
Contact: Donna Zwirner, M.S
Senior Account Manager
Tel: (800) 252 4752 Ext. 8477 Fax: (508) 482 3373

OriGene
Your gene company
9620 Medical Center Dr.
Suite 200
Rockville, MD 20850
Contact: Xuan Liu, Ph.D., Marketing
Tel: 240-620-0234, Fax: 301-340-8606
Email: xliu@origene.com
www.origene.com

DiscoveRx Corporation
42501 Albrae St
Fremont, CA 94538
www.discoverx.com
Contact : Abhishek Saharia
Director, Cell-based Assays and Biologics
Tel: 443-955-0930, Fax : 501-979-1650
E-mail: asaharia@discoverx.com
www.discoverx.com | www.biomapsystems.com

Promega
2800 Woods Hollow Road
Madison, WI 53711
Contact: May Guo, Sr. Field Application Specialist II
Tel: 240-281-1001
Email: may.guo@promega.com
www.promega.com

Zhejiang Teruisi Pharmaceutical Inc
3rd Floor, Building 5,1366 Hongfeng Road
Huzhou, Zhejiang, China 313000
Contact: Youling Wu, Ph.D
Chairman and CEO
Tel: (+86) 18668109601
Cel: (+86) 18668109601
Fax: （86）0572-2126820
E-mail: youling.wu@teruisipharm.com
www.teruisipharm.com

CanSino Biotechnology LTD.
220 Dongting Road,
Tianjin Economic-Technological Development Area,
Binhai New Area, Tianjin 300457
Contact: Xuefeng Yu
Tel: 4849195460

E-mail: xuefeng.yu@cansinotech.com
www.cansinotech.com

Ascentage Pharma Group Corp Limited
亚盛医药
11/F AXA Centre, 151 Gloucester Road, Wanchai, Hong Kong
江苏泰州市药城大道 QB3 大楼（国家新药创制基地）
上海浦东张江高科技园区蔡伦路 780 号 3 楼 P 座
Contact: Dajun Yang, M.D., Ph.D., President & CEO
Tel: 0523-86201369; 021-51320510
E-mail: dyang@ascentagepharma.com
www.ascentagepharma.com

ChemPartner
Brent Hehl
Associate Director, Business Development
Tell: (919) 675-2585 (US EDT)
Email: bhehl@chempartner.com
www.ChemPartner.com

JSR Micro, Inc.
1280 N. Mathilda Ave.
Sunnyvale, CA 94089
Pam Zapffe
Trade Show Manager
pzapffe@jsrmicro.com
Doug Pagano
National Sales Manager
Life Science and Emerging Technologies
dpagano@jsrmicro.com
http://www.jsrmicro.com

GenScript
860 Centennial Ave.
Piscataway, NJ 08854
Contact: Ray Chen
Office phone: 732-885-9188 ext.178
Cell: 732-570-9148Fax: 732-210-0262
Email: ray.chen@genscript.com
www.genscript.com

Noegen Inc.
诺京生物信息公司
PO Box 83718
Gaithersburg, MD 20883
Contact: Cathy Chen
Executive Market Associate
Tel: 301-767-0288, Fax: 301-767-0188
www.noegen.com

Sepax Technologies, Inc.
Helen Gu
Vice President, Sales & Marketing
Direct Phone: 302-650-3909
Main Phone: 877-SEPAX-US
Email: hgu@sepax-tech.com
www.sepax-tech.com

NFCR
National Foundation of Cancer Research
4600 East West Highway, Suite 525
Bethesda, MD 20814
Contact： Sujuan Ba, Franklin C. Salisbury, Jr.
Tel: 301-654-1250 Fax: 301-654-5824
www.NFCR.org

Tianjin Junyao Trade Co., Ltd
109 Bawei Road, Hedong District
Tianjin, Tianjin, China
Contact: Lianying Yu
Tel: 86-13821347678
www.kingyork.biz/otherwebs/tianyaoguomaowebsite/en-index.html

Sirnaomics, Inc
401 Professional Dr, Ste 208
Gaithersburg, MD 20879
Contact: Alice Zhang
Tel: 301 740-1730
Email: az@sirnaomics.com
www.sirnaomics.com

Presentation Abstracts and Speaker Biographies

Xu-Rong Jiang, M.D., Ph.D., Quality and Technical Director
AstraZeneca BioVentures and Global Biologics Operation
President Elect of the Chinese Biopharmaceutical Association-USA (2016-2017)
Phone: (301) 915-6081
E-mail: JiangX@MedImmune.com

Biography: Dr. Xu-Rong Jiang is currently a Director of Quality and Technical, AstraZeneca BioVentures and Global Biologics Operation. The AstraZeneca BioVentures Business is a newly established unit within AZ to develop Biosimilars and BioBetters jointly with leading biotech companies in China and other Asian countries for the global markets. Prior to his current responsibility, Dr. Jiang had served as an Associate Director in Analytical Biotechnology at MedImmune since 2008. He headed the Biological Development Group in support of biologics analytical method development for IND filing, GMP testing, technology transfer and process development. Prior to MedImmune, Dr. Jiang was a Principal Scientist in Process & Analytical Sciences at Amgen where his group was responsible for development, qualification, validation of potency assays for biologics development. Prior to Amgen, Dr. Jiang was a Senior Scientist at Geron Corporation focusing on gene and cell therapy, high throughput screening, and regenerative medicine with embryonic stem cells. Dr. Jiang received his Ph.D. degree in Molecular Cell Biology, University of London. He also had an M.D. in Hematology from China Medical University. Dr. Jiang has served at various scientific and professional organizations and committees. He is an Associate Director for CASSS, an International Separation Science Society. He has been a member of Scientific Organizing Committee for CASSS Bioassays since 2011. Dr. Jiang has also served as an organizing committee for the Cell-based Assay Action Program Committee, American Association for Pharmaceutical Scientists. He has published more than 26 journal papers and is an assignee of three U.S. patents. Dr. Jiang has been the President-elect and served as a Board of Director of the Chinese Biopharmaceutical Association-USA in 2015-2016.

Shou-Bai Chao, Ph.D., Senior Vice President
AstraZeneca BioVentures
President of the Chinese Biopharmaceutical Association-USA (2015-2016)
Phone: +86 185-2106-6700 (China), +1-240-780-6488 (US)
Email: sbchao@icloud.com

Biography: Dr. Shou-Bai Chao is President of Chinese Biopharmaceutical Association-USA (2015-2016), Dr. Chao serves as Senior Vice President in AstraZeneca leading AZ's BioVentures

business globally and specifically in China and Asia. Dr. Chao leads a dedicated team to develop Biosimilars and BioBetters with leading biotech companies in China and other Asian countries for the global markets. Dr. Chao relocated to Shanghai AZ headquarter in 2014 from Medimmune in Maryland, USA. Prior to the current responsibility, Dr. Chao was Senior Vice President of Technical Operations and Manufacturing at Medimmune, a biological division of AstraZeneca. He was responsible for global operations of commercial and later stage clinical products (vaccines and antibodies) manufacturing and technical operations. Dr. Chao joined MedImmune in 2008 as vice president of vaccine manufacturing, responsible for all aspects of global vaccine manufacturing and supply. He also contributed to Medimmune's commitments to pandemic preparedness. Prior to joining Medimmune, Dr. Chao served as assistant vice president, Technical Operations and Product Supply at Wyeth Biotech. He was responsible for global technical operations for the flagship vaccine, Prevnar(R) and other Biopharmaceuticals. He brings comprehensive perspective with more than 20 years of experience at Medimmune, Wyeth, Sanofi-Pasteur and Genentech in global vaccine and biopharmaceutical process and product development, manufacturing operations and quality assurance. Dr. Chao earned his doctorate and completed his postdoctoral fellowship in Biochemical Engineering from University of Waterloo, Canada.

Biography: Mr. Li Kexin was born in January 1969. He holds a PhD in Economics.

2015.4 -present	Minister, Embassy of the People's Republic of China in the United States of America
2012.10-2015.04	Deputy Director-General, The Department of International Economic Affairs, Ministry of Foreign Affairs
2010.07-2012.10	Counselor, then Deputy Director-General, The Department of International Organizations and Conferences, Ministry of Foreign Affairs
2006.03-2010.07	Counselor, Permanent Mission of the People's Republic of China to the United Nations
2004.03-2006.03	Deputy Mayor Duyun City, Qiannan Buyi and Miao Autonomous Prefecture, Guizhou province
1999.09-2004.03	Deputy Division Director, then Division Director, the Department of International Organizations and Conferences, Ministry of Foreign Affairs
1998.09-1999.09	Postgraduate at the London School of Economics and Political Science, UK
1991.08-1998.09	Desk Officer, Attache, then Third Secretary, the Department of International Organizations and Conferences, Ministry of Foreign Affairs
1987.09-1991.08	Undergraduate student, Beijing International Studies University

2016 CBA Brilliant Achievement Award Presentations

A Dream, a Platform, and a Transformation

Biography: Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi AppTec, a premier open access R&D enabling platform company serving the global pharmaceutical, biotechnology and medical device industries. Dr. Li has led WuXi since its founding in 2000, and has grown the company from four employees and a 7,000 square feet single lab to a global footprint of 5.5 million square feet across 24 sites and over 10,000 employees worldwide. The integrated R&D platform model Dr. Li pioneered is now the cornerstone of WuXi's industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. Together, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Dr. Li's industry leadership and achievements have won him numerous prestigious awards and honors, including "2015 SCRIP Executive of the Year Award," "The 25 Most Influential People in Biopharma in 2015," "Forbes 25 Notable Chinese-Americans," "The 60 Most Influential People during 60 Years Pharmaceutical Development in China," and "Ernst & Young Entrepreneur of the Year China Award." WuXi has also been recognized with distinguished honors such as "Asian CRO Company of the Year" Award (2015) , "North American Open-Access R&D Technology Leadership" Award (2015), "Best Company in an Emerging Market" (2014), and listed for 6 consecutive years on "Deloitte Technology Fast 500 Asia Pacific" (2004-2009), and "Fast Company 50 Most Innovative Companies" (2009). Dr. Li received his B.S. in Chemistry from Peking University and Ph.D. in Organic Chemistry from Columbia University. He was a founding scientist at Pharmacopeia Inc., a leading combinatorial chemistry platform company before the founding of WuXi.

Abstract: Despite tremendous scientific and technological advances over the past decades, the introduction of new therapeutics and healthcare products continues to face major challenges. Demand for new and more affordable therapies has never been greater, and many have come to understand that no single company – no matter how committed to patients – can overcome these challenges on its own. Better Medicines Faster for patients requires open-access approaches to lower the entry barrier for innovation, and to harness collective capabilities and experience to improve the odds of success. WuXi's mission is to build and strengthen an open-

access capability and technology platform to enable anyone and any company to discover and develop pharmaceuticals and healthcare products to benefit patients.

Bahija Jallal, Ph.D.
Executive Vice President of AstraZeneca and
Head of MedImmune
Phone #: 301-398-5268
E-mail: jallalb@medimmune.com

Biography: Dr. Bahija Jallal is Executive Vice President of AstraZeneca and head of MedImmune, the global biologics research and development organization. She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006. Dr. Jallal is passionate about leading and shaping MedImmune's rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and metabolic diseases and pain to ultimately develop new medicines for patients. Dr. Jallal is a member of the Board of Trustees of the Johns Hopkins University and is on the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark. She is the incoming president of the Association for Women in Science.

Session 1: Regulatory Challenges and Opportunities in China and US

Chairs: Dan Zhang, M.D., President & CEO, Fountain Medical Development Ltd, and **Qiao Bobo**, Ph.D., Review and Inspection Officer, FDA

Dan Zhang , M.D., MPH, Chairman and CEO
Fountain Medical Development Ltd.
Phone #: +86-136-1114-2168
E-mail: dzhang2@hotmail.com

Biography: Dr. Dan Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 400 employees operating in South East Asia, China and USA. Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc., He was a vice president at the Quintiles Transnational Corp. and the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., Dr. Zhang is a member of grant application review committee for National Key Drug Development Fund of China He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and is the secretary-general of the Association of "Thousand Talent" Expert. Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master's degree in healthcare management in 1998.

Qiao Yu Bobo, Ph.D., Team Lead
Food and Drug Administration
Phone #: (240) 402-9403
E-mail: yuqiao@hotmail.com

Biography: Qiao Yu Bobo, PhD currently serves as Lieutenant Commander (LCDR) in the United States Public Health Service and also serves as a Team Lead and Acting Branch Chief in the Division of Manufacturing and Product Quality (DMPQ), Office of Compliance and Product Quality, Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration.

She oversees the review of submissions and inspection of biological drug/vaccine manufacturing facilities in the United States and overseas. Prior to her position as a Team Lead, Dr. Bobo was a reviewer and lead inspector in DMPQ. Prior to joining FDA, Dr. Bobo had more than a decade of experience in the field of vaccine development and gene therapy with biopharmaceutical companies including MedImmune and Advanced BioScience Laboratories Inc. She has published multiple peer reviewed articles and presented at numerous conferences and workshops. Dr. Bobo received her PhD in Cell and Molecular Biology from the University of Vermont, and BS in Biology from Fudan University China.

New Policies and New Regulatory Strategy in China

Yi Feng, VP of Regulatory and Medical Affairs,
Fountain Medical Development Ltd.

Email: yi.feng@fountain-med.com

Biography: Mr. Yi Feng is a senior VP for regulatory & medical affair of Fountain Medical Development Ltd.(FMD). Before joining FMD, he had 2-year experience as a consultant in a law firm. Mr. Feng worked for five years as an orthopedic surgeon in his early career, and as a regulator for 17 years at the China Food and Drug Administration (CFDA) Center for Drug Evaluation (CDE). During his long tenure at the CFDA CDE, Mr. Feng held several leadership positions and developed very broad and deep expertise on CFDA regulatory and scientific matters.

Abstract: In the past year, CFDA had issued many news policies that impact the Chinese drug stakeholders. How to assess the policies, where is the future opportunity for innovative drug development in China and what is the key issue for simultaneous clinical trial? This presentation will cover all these hot topic areas.

Regulatory Challenges and Opportunities in Companion Diagnostics

Yun-Fu Hu, Ph.D., RAC Deputy Division Director
Division of Molecular Genetics and Pathology

Office of *In Vitro* Diagnostics and Radiological Health
Center for Devices and Radiological Health
Food and Drug Administration
Phone #: 301-796-6170
E-mail: yun-fu.hu@fda.hhs.gov

Biography: Dr. Hu is currently the Deputy Director of the Division of Molecular Genetics and Pathology in the Office of *In Vitro* Diagnostics and Radiological Health at FDA's Center for

Devices and Radiological Health. He completed his undergraduate studies in China, and received his M.S. and Ph.D. degrees from the Ohio State University. After 5 years at Fox Chase Cancer Center, he joined Becton Dickson as a Project Scientist leading the development of a molecular diagnostic test for melanoma. He led biomarker discovery and test development at GSK as an Investigator and then Group Manager for 5 years before joining Metabolon as the Director of Diagnostics Development to oversee its diagnostics research and development programs in 2007. He joined FDA as a Scientific Reviewer in 2009 and was promoted to Associate Director in 2011. He became the Chief of the Molecular Pathology and Cytology Branch of the Division of Molecular Genetics and Pathology in 2012 and assumed his current position in 2015. His Division is responsible to enforce or carry out the provisions of the Food, Drug, and Cosmetic Act as it relates to testing and acceptance of molecular genetics devices, pathology and cytology devices, cancer diagnostics and companion diagnostics.

Abstract: Remarkable advances in the understanding of molecular mechanisms influencing neoplastic development and progression have spurred interest in molecular diagnostics and targeted cancer therapeutics. Approximately one in five original novel drugs approved by the US FDA since 2010 is considered a "targeted" therapy. Diagnostic tests that are essential to the safe and efficacious use of a drug are called "companion diagnostics". Co-development and co-approval of therapeutics and companion diagnostics have provided significant benefits to many cancer patients. However, the current co-development and co-approval paradigm has also brought many scientific, economical and regulatory challenges that pharmaceutical companies, device manufacturers, clinical labs and regulatory agencies will have to work together to overcome. With the advent and rapid adoption of next generation sequencing (NGS) technology for biomarker identification and clinical testing, it is conceivable that NGS may soon become the platform of choice to be used for genetic testing of a large array of genes for guiding patients to different targeted therapies. This presentation is intended to provide an overview of FDA regulation of companion diagnostics and discuss some regulatory challenges and opportunities for development of targeted therapeutics by pharmaceutical companies and device manufacturers.

Current Challenges in the Regulatory Landscape for US and China

John Finkbohner, Ph.D., Senior Director, US RA
MedImmune
Phone #: 301-256-7490
E-mail: FinkbohnerJ@MedImmune.com

Biography: Dr. Finkbohner joined the regulatory affairs department at MedImmune in 2006 and led the regulatory efforts supporting investigational vaccine development for nearly six years. In early 2012, he transitioned to the Regulatory Policy function where he is responsible for driving regulatory policy development and advocacy in the US region with particular focus

on articulating a consolidated view on regulatory issues relevant to the biologics business. In this role he engages external trade organizations, facilitates developing policy positions around biosimilar products and PDUFA reauthorization, and served as an innovator industry representative during the original BSUFA negotiations with the FDA. Prior to joining MedImmune in May 2006, Dr. Finkbohner served in the FDA for 13 years as a CMC reviewer and establishment inspector with increasing levels of authority. His last position in FDA was with CBER as Deputy Director of the Division of Manufacturing and Product Quality with responsibilities in oversight of CMC and ED section reviews for BLAs, conduct of preapproval inspections for biologics, the CBER lot release program, and policy development in the biologics manufacturing arena.

Abstract: The regulatory challenges faced during drug development differ between the US and China, but overall regulatory health authority best practices center around transparency in communication of regulatory expectations, and consistency in regulatory requirements. In the US, the managed review process instituted under the Prescription Drug User Fee Act (PDUFA) has brought definition to regulatory review timelines with specified communication milestones. These communications "milestones" ensure opportunities for sponsors and regulators to meet, ensuring that relevant regulatory expectations are defined and permitting the resolution of regulatory questions in a more predictable manner. Current challenges in the US regulatory environment are centered around issues that are evolving and/or changing due to the nature of innovative drugs and the changing healthcare environment (e.g., enhancing patient voice in drug development, bringing more formal benefit/risk frameworks to regulatory decision making, etc). Challenges in bringing new drugs to China are related to the length of time required for the review of CTAs and NDAs in China; topics for which regulatory guidance is limited or not available; and, the broader context of developing drugs in a global environment (e.g., efficient conduct of multiregional clinical trials including China). Some of these challenges in drug development for both the US and China will be discussed in more depth.

Jinjie Hu, Ph.D., Senior Consultant
Biologics Consulting Group, Inc.
Phone: 301-814-4985
Email: jhu@biologicsconsulting.com

Biography: Dr. Hu joined Biological Consulting Group (BCG) in 2012 after working for the Food and Drug Administration for almost 12 years where she was a senior expert regulatory/scientific reviewer for multiple analytes In Vitro Diagnostic Devices (IVD) products. She is recognized as the IVD expert on FDA regulation and QSR requirement. Dr. Hu has led and chaired many review committees for 510 (k), IDE, PMA, IND and BLA. She also served as a training committee member and instructor for the annual Medical Device Training course at CEBR/FDA for 4 years (2009-2012). As a Senior Consultant for IVD devices, she advises clients

on the regulatory requirements for IVD products in the US, on product development and study designs, and on short and long term regulatory strategies for the development and approval of IVD device technologies, combination products and companion diagnostic products. In addition, she prepares pre-submission packages/agendas for all FDA type meetings for Pre-IDEs, IDEs, pre INDs and INDs, 510(k)s, 513(g), PMAs and BLAs as well as CLIA waiver applications. She represents clients in interactions with the FDA and negotiates least burdensome approaches and alternative study plans. She also conducts quality system audits for manufacturing facilities and advises on responses to FDA 483 deficiency items. Dr. Hu received her B.S. in Cell Biology from Beijing Normal University and her Ph.D. in Comparative Pathology from University of California, Davis, followed by a postdoctoral fellowship at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Session 2: Immune-oncology and Cell Therapy

Chairs: Yingxian Xiao, **Ph.D.,** President & CEO, Potomac Pharmaceuticals, Inc., and **Yuling Li**, **Ph.D.,** Scientific Director, MedImmune

Yingxian Xiao, Ph.D.
President and CEO
Potomac Pharmaceuticals, Inc.
Phone: 301-765-9574
E-mail: TheraGene@aol.com

Biography: Dr. Yingxian Xiao is an associate professor of pharmacology and Physiology in Georgetown University School of Medicine. He received his B.S. in microbiology from Northwestern University and his M.S. in microbiology from Institute of Microbiology, Chinese Academy of Sciences. He studied molecular biology at the University of Maryland at College Park and received a Ph.D. in 1994. After a three year post-doctorate in molecular pharmacology at Georgetown University, working on pharmacological properties of neuronal nicotinic acetylcholine receptors, he joined the faculty of Department of Pharmacology in 1997. Dr. Xiao's research interests are on molecular pharmacology of nicotinic receptors, mechanism of ligand-receptor interactions and developing new CNS therapeutics targeting nicotinic receptors. He has authored and co-authored more than 60 peer-reviewed papers. He is listed as inventor in 7 patents and patent applications. Dr. Xiao was a founding member of the Chinese Biopharmaceutical Association – USA (CBA) in 1995. He has served as a member of CBA Board of Directors since 1997. Dr. Xiao served as the CBA president from 2003 to 2004. He was the recipient of 2008 CBA Outstanding Service Award.

Yuling Li, Ph.D.
Fellow (Scientific Director), BioPharmaceutical Development,
MedImmune, A Member of the AstraZeneca Group
Email: **LiYu@MedImmune.com**

Biography: Dr. Yuling Li is the former President (2007-2008) of the Chinese Biopharmaceutical Association-USA (CBA). Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. Dr. Yuling Li has more than 20 years of biopharmaceutical development experience. She is currently a R&D Fellow (Scientific Director) at MedImmune, responsible for providing input on scientific/technical directions and strategies for process development activities. She leads multiple technical teams and several mid to late

stage projects. She also heads the MedImmune postdoctoral committee and served as a postdoc mentor. Prior to joining MedImmune, Dr. Li was the Senior Director at Human Genome Sciences Inc. (Rockville, MD, now GSK). Dr. Li has contributed to bringing many biopharmaceuticals, including monoclonal antibodies, recombinant protein therapeutics and a small molecule drug to various stages of clinical development, BLA preparation and commercial readiness. Before joining HGS, Dr. Li was at Hoffmann-La Roche Inc. in Nutley, New Jersey. She has been a long time member of industry expert groups working with the FDA, EMA and USP to address issues and guidelines associated with biopharmaceutical development. She received the Rising Star Award in 2014 from the Healthcare Businesswomen Association (HBA, http://www.hbanet.org/).

Facing Future Challenges—From Conception to Realization, a Development Platform at China's Ban Tang Biopharmaceuticals

Biography: Wenbo Cao, PhD of Management Sciences, is currently the Chairman of Board of Directors for Anhui QianDao Investment Management Company. Dr. Cao also holds the positions of the President of Weimin Biotechnology and Environmental Protection Company, the President of Anhui Weimin Biotechnology Economics Group Limited, the President of Qinhuangdao Weimin Health City Development Limited, The President of HeChao Economic Development District Entrepreneurs Association. Dr. Cao was named as one of the Hefei City's Ten Figures of Science, Technology and Innovation. Dr. Cao is an expert in the field of industrial planning and city urban design and planning. His work on "Planning Genetics" and "Inner Circle Management Systems" improved the bio-economics theories. He put the theories into practices and established a new type of "Area economic development and transition model", and he established the first biotechnology economic experimental area within two years in Anhui Hefei city. It was named as "Ban Tang Model, Weimin Speed, Wenbo Efficiency".

The Power of Combinations in Immuno-oncology

Tony Ho , M.D.
Global Medicine Leader Durvalumab Multiple Indications, Vice President
ImmunOncology GMD**,** AstraZeneca Pharmaceuticals, LP
Phone: 267-328-7154
E-mail: Tony.Ho@astrazeneca.com

Biography: Tony is an ImmunOncology Vice President at AstraZeneca, currently leading the Durvalumab (MEDI4736, anti-PD-L1) program after he led the development and approval of Lynparza. Tony most recently co-authored two oncology review articles on oncology drug development and the use of intermediate endpoint. Prior to joining AstraZeneca, Tony was the head of Neurology and Ophthalmology at Merck and led several Phase III programs including CGRP receptor antagonist for migraine, A2a receptor antagonist for Parkinson's disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer's disease, and alcohol abuse. He has pioneered several novel pain trial designs and has also devised several strategies in decreasing placebo rate. Prior to joining Merck, Tony was the Co-Founder and Chief Scientific Officer of Neuronyx, a start-up company that developed stem cells for heart failure and immune-oncology. Tony completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University. He was Assistant Professor at Johns Hopkins Hospital specialized in neuropathy and neuromuscular diseases. Tony describing and elucidating the pathogenesis of a new disease called "acute motor axonal neuropathy (AMAN)". He is currently Adjunct Associate Professor at University of Pennsylvania and Assistant Professor (Part-time) at Johns Hopkins University.

Abstract: Monotherapy anti-PD-L1/PD1 has shown remarkable durability of response in a small subset of patients across many tumor types. However, majority of patients still only derived limited benefit from monotherapies. These patients can be categorized broadly as those who are inflamed non-responsive and who are non-inflamed non-responder. How to overcome both adaptive and innate resistance and how to convert cold tumor to hot tumor with novel combinations are current area of intense research. I will review the latest progress and insight in this area.

Linda Liu, Ph.D.
Vice-President of Translational Research
NextCure Inc.
E-mail: lnliu333@gmail.com

Biography: Dr. Linda Liu currently is the Vice President of Translational Research at NextCure, Inc., a newly formed biopharmaceutical company focused on the discovery and development of new immuno-oncology products. She has more than 20 years of research and industry experience with broad knowledge and proven success in the discovery and development of biological drug candidates in oncology and autoimmune diseases. She was one of the founding scientists at Amplimmune, a member of AstraZeneca Group, where she held various key positions with increasing responsibilities, including Executive Director of Translational Science/Scientific Affairs and VP of New Products. Prior to that, she served as Senior Director of Biological Product Development at MaxCyte, where she was responsible for development, *in vitro* and *in vivo* characterization and manufacture of various gene & cell based therapeutics including CAR-T, CAR-NK & DC therapies. Dr. Liu is an author or co-author of many research and review articles in peer-reviewed journals and book chapters in the areas of cancer immunotherapy, gene/cell therapy and cell biology. She is an inventor of numerous US and European patents and patent applications. Dr. Liu received her PhD degree from the University of Texas, Austin and her BS degree from Wuhan University in China. She conducted her postdoctoral training in Tumor Cell Biology at the St. Jude Children's Research Hospital.

Luncheon & Sponsor Presentations

Chairs: Min Zhu, Ph.D., Principal Scientist, MedImmune, and **Kun Yao**, Ph.D., Director, AstraZeneca

Min Zhu , Ph.D.
Principal Scientist, MedImmune/AstraZeneca
Phone: 301-398-4617
E-mail: min.jerry@gmail.com

Biography: Min Zhu has over 12 years of biopharmaceutical industry experience in process development, characterization, manufacturing and validation support. Currently, Dr. Zhu is a Principle Scientist of Biopharmaceutical Development at MedImmune, a member of the Astra Zeneca group. Before joining MedImmune, she worked as a Process Engineer at Lonza. Previously, Dr. Zhu was a Senior Scientist of Critical Reagent and Formulation, responsible for antibody and conjugation reagent development and GMP manufacturing. Dr. Zhu has served in Howard County Chinese School as a director in Board, a member of Executive committee and a PTA chair. She also served as a volunteer in Parents' Committee of Johns Hopkins and local high school and middle school. She is also organizing a photographic club and actively involved in local art competition and exhibition. She is an active speaker in professional conferences, as well the career development workshop. Dr. Zhu was born in Shanghai and received the B.S. and M.S. degree in Chemistry from Fudan University and Ph.D. in Chemistry from Nankai University in China. She was a post-doc fellow at Max-Plank Institute and University of California, Santa Cruz.

Kun Yao, Ph.D.
Director**,** AstraZeneca
Phone: 215-300-1385
E-mail: quinnyao2010@gmail.com

Biography: Kun Yao, Ph.D., is currently Director of Global Technical Operation at Medimmune, and Biological Division of AstraZeneca. He has over 16 years of pharmaceutical experience in vaccines and therapeutic biologics CMC development covering clinical development and commercial products. Dr. Kun Yao had worked in Wyeth Vaccine Research from 1999 to 2009 with experience in vaccine development and commercialization focusing on product characterization, process development support, method development and validation, and GMP testing. Some of the key vaccine

development/commercialization projects included Influenza vaccine (FluMist®), Pneumococcal Conjugate Vaccine (Prevnar 7®and Prevnar 13®), and Neisseria meningitides Type B vaccine (Trumenba®). Dr. Yao joined Medimmune in 2009, as an associate director and head of MSAT at the Philadelphia site, responsible for leading FluMist® fill/finish technical operation. He has provided technical leadership for monovalent bulk productions, finished products, QC potency testing and product stability testing. He was one of the major contributors to MedImmune commitments to 2009-2010 H1N1 pandemic preparedness. In 2011, he joined MSAT at FMC, and lead analytical/QC team for method qualification, validation and technology transfer for late-phase clinical development products, including internal and external therapeutic monoclonal antibodies (mAb) drug candidates. He has worked with external Trustee Partner Network (TPN) to complete CMC activities for process characterization, process validation and BLA filing support of the first anti-PD-1 (programmed death receptor-1) therapy, approved USA Breakthrough Therapy product for advanced melanoma (Keytruda®) in September 2014. Dr. Yao received his Ph.D in molecular virology and immunology from the University of Maryland at College Park (1998) and completed his postdoctoral fellowship at the Institute of Human Gene Therapy from University of Pennsylvania School of Medicine, Philadelphia, USA. Dr. Yao is author/co-author of 30+ papers, book chapters, patents and abstracts, and is co-inventor of 2 US/international patents related to vaccine development.

Market Trends for Consultants within Pharmaceutical Industries

Rav Mahal, Ph.D.
Managing Consultant at PharmEng Technology
Phone #: (416) 303-3902
E-mail: rav.m@pharmeng.com

Biography: Rav Mahal holds a Ph.D. and Post Doctoral in Organic Chemistry from University of Salford, England and sits on the Board of Directors, Canadian Society for Pharmaceutical Sciences (CSPS). He has over 26 years of experience in product development, project & business management, client services, strategic planning and P&L in active pharmaceutical ingredients, fine chemicals, pharmaceutical and contract manufacturing industries. Rav Mahal has delivered on time and on budget pharmaceutical development projects and commercial launches (solid & liquid dosages) while optimizing resources, generating significant cost savings and promoting innovative solutions in complex environments.

Abstract: The presentation will cover areas of increase support for consulting services with the Pharmaceutical companies. The subjects covered with examples of case studies will be Serialization, C&Q, Data Integrity and Validation

MilliporeSigma, A business of Merck KGaA

Sylvia Mannino
Account Manager Consultant, Pharma Processing
A business of Merck KGaA, Darmstadt, Germany
EMD Millipore Corp. Billerica, MA 01821 USA
Phone: 443 244 5104

Biography: Sylvia Mannino is an Account Manger Consultant at MilliporeSigma, A business of Merck KGaA. She has a BS in Chemical Engineering from Penn State University and has over 30 years of experience in the Pharm/Bio Industry supporting Process Development and Manufacturing for upstream and downstream biopharmaceutical processes with emphasis on mAb processes. She has expertise in scale up, tech transfer and process optimization. She lives in Baltimore, Maryland USA.

Abstract: Industry trends are forcing bio-manufacturers to adopt a more strategic view of manufacturing. This short discussion will review the key factors and drivers in this new approach to manufacturing. This discussion will review strategies for solving process and facility bottlenecks.

Talent Recruitment at Luye Pharma

Xiufang Zhang
HR Manager
Luye Pharma Group
E-mail: zhangxiufang@luye.cn

Abstract: Luye Pharma Group is a professional pharmaceutical enterprise built on a solid foundation of research and development, focusing on the largest and fastest growing therapeutic areas——oncology, cardiovascular system, alimentary tract and metabolism, and central nervous system. The company was founded in 1994 and now has approximately 4,000 employees, including more than 300 R&D specialists. Luye Pharma is persistent pursuit of innovation and internationalization, and will endeavor to become one of the top 100 global pharmaceutical companies by 2020. Luye Pharma currently has 7 product candidates for overseas markets: one is preparing to submit NDA application; three are undergoing clinical trials in the US and one will start clinical trials in the US soon. To meet business needs, Luye is actively recruiting talents for the positions both in U.S and China.

Session 3: Global Collaborations

Chairs: Gayatri Varma, Ph.D., Director, MedImmune, and **Ziping Wei**, Ph.D., Executive Director, Novavax, Inc.

Collaborations & Partnerships at MedImmune

Gayatri Varma, Ph.D., Director, Partnerships
MedImmune
Phone #: 301-398-1947
E-mail: varmag@medimmune.com

Biography: Dr. Gayatri Varma is currently Director, Collaborations Partnering and Strategy at Medimmune. She was previously Executive Director of the Office of Technology Commercialization, University of Maryland College Park, MD. Dr. Varma joined the OTC team in 1997 as a graduate student to assist with the evaluation and marketing of the university's life science technologies and rose through the ranks. Working with the College of Life Sciences, Dr. Varma has been instrumental in instituting bi-monthly office hours for faculty, staff, and students to discuss their research, the technology transfer, commercialization, and patenting processes, and alternative careers. Due to the success of Life Science office hours, Dr. Varma has helped MTECH implement its own monthly entrepreneur office hours. She is a registered Patent Agent with the U.S. Patent and Trademark Office. Dr. Varma has a B.Sc.in microbiology from Bombay University, Bombay, India, a M.Sc. in microbiology from M.S. University in Baroda, India and a Ph.D. in molecular and cell biology from the University of Maryland.

Abstract: At MedImmune, our goal is to push to boundaries of science to deliver life changing medicines to patients. To achieve this we have to access the best science there is. In the quest to achieve the best science, collaboration is key. Innovation does not happen in a vacuum so we collaborate with partners within academia, governments, and industry around the world. This allows us to work with world class organizations as well as contribute complementary technologies, know-how and molecules. Our partnerships are tailored to result in successful medicines administered to patients.

Ziping Wei, Ph.D., Executive Director
Novavax, Inc.
Phone: 240-888-2704
E-mail: zwei@novavax.com

Biography: Dr. Ziping Wei is the Executive Director of vaccine product development at Novavax, Inc. She has more 20 years' industrial experience of developing recombinant therapeutic protein and vaccine products at several biopharmaceutical companies in US. Her expertise includes product characterization and comparability, method development, release and stability testing, technology transfer, and process development support of products at various stages of pre-clinical and clinical development, and post-market commercialization. Prior to working at Novavax, Dr. Wei was Scientific Director in Biopharmaceutical Development and led product development efforts for recombinant therapeutic protein and vaccine products at MedImmune, AstraZeneca. She held positions at Bristol-Myers Squibb, R. W. Johnson Pharmaceutical Research 9Institute (Johnson & Johnson), and the Center for Advanced Biotechnology and Medicine in New Jersey. She received her Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China. Dr. Wei has experience in working on product development and technology transfer with international biopharmaceutical companies in China, India, United Kingdom, Austria, Sweden, and Germany. She has co-authored more than 100 journal publications, patents, book chapters, scientific abstracts and presentations, and holds multiple U.S. and international patents. She has been invited to give oral presentations and short courses at national and international conferences. Dr. Wei is a former President of the Chinese Biopharmaceutical Association (CBA-US).

中国药物创新国际化合作发展趋势与模式创新

Development Trend and Model Innovation: Innovative Drug Internationalization in China

Guozhong Rui, Ph.D., Director of China Pharmaceutical Technology Transfer Center (CPTTC)/ Executive Secretary-General of China Association for Pharmaceutical Enterprises Development
Phone #: +86 13901079450
E-mail: rui@pharmtec.org.cn

Biography: Dr. Guozhong Rui has published many papers in academic journals, and gives multiple lectures at domestic and international forums every year. He is a senior expert of

pharmaceutical technology economics & management in China. He has received numerous Awards and Honors from Ministry of Science and Technology and Beijing Municipal Government. Dr. Rui is the Director of China Pharmaceutical Technology Transfer Center (CPTTC) and the Executive Secretary-General of China Association for Pharmaceutical Enterprises Development. Also he is the Chairman /General Manager of Beijing Sinovate Sunshine Pharmaceutical Technology Development Co., Ltd. and Shanghai Fengxian Biological Technology Development Co., Ltd. Dr. Rui is a panelist of Torch Program and Hi-tech SME Technology Innovation Fund of Ministry of Science and Technology. He works as a visiting professor in many universities and institutes; he is also the senior advisor of some famous pharmaceutical companies. He has conducted intensive research for more than 30 years and accumulated seasoned experience in biomedical and pharmaceutical technology development, technology transfer, clinical trial, registration, technology evaluation, technology management, intellectual property protection, program feasibility study, as well as technology economics & management.

Abstract: China's pharmaceutical industry contains huge development potential, has become a representative of the future global emerging bio pharmaceutical market. Therefore, China is bound to become global biopharmaceutical industry chain transfer locations. How to make full use of the opportunity of the global pharmaceutical industry chain to speed up the transfer to emerging markets, to achieve the integration of depth and international innovation resources, which requires not only our country all levels of government, pharmaceutical companies, research institutions, investment financing and technology services institutions with a more international perspective and open innovation concept and innovation (technology licensing, cooperative development mode of international scientific and technological cooperation and technology platform + venture capital fund combination, etc.), which is to enhance the innovation ability of pharmaceutical enterprises in China, as well as industrial restructuring and upgrading and the development of the globalization of the key.

Develop and Manufacture Global Quality Biopharmaceuticals in China

Youling Wu, Ph.D., CEO
Zhejiang Teruisi Pharmacuticals Inc.
Phone #: (+86) 0572-2167260, Mobile: 18668109601
E-mail: youling.wu@teruisipharm.com

Biography: Dr. Wu currently holds the CEO position of Zhejiang Teruisi Pharmaceutical Inc. that is located in Huzhou, Zhejiang, China focusing on Biopharmaceutical research/development and commercial production. Manage company routine operation, business model/strategies, budget planning and raising fund.

Past US pharmaceutical/biopharmaceutical industry experiences: broad based experiences in biopharmaceutical industry including management: director, associate director of Analytical Development, CMC-Regulatory and Global Quality Control. More than 26 years experiences in biotech division of big-pharmaceutical companies（BMS and J&J）and mid-size innovated biotech companies (Genzyme and Seattle Genetics) in multiple disciplinary functional areas: analytical development, quality control, Regulatory-CMC, CMC team leader involving variety disease areas such as oncology, cardiovascular, immunology/infectious disease and recombinant vaccines. Participated or led 6 mAb blockbuster product (Orencia, belatacept, Remicade, Stelera, Golimumab and Brentuximab- ADC) development including phase 1, 2, 3 clinical development and commercial launch. Managed multi-million dollar budget and established new function for late phase development projects (phase 3). Proficient with regulations and participate in FDA-Biopharmaceutical Industry strategic communications. Responsible for and managed Regulatory CMC strategy, prepared documents for multiple nation (US, EU and Canada) regulatory submissions (IND, IMPD, CTA, BLA and NDA) including a fast track project for priority review and accelerate approval.

Abstract: China Biopharmaceutical industry is blooming and there are many opportunities and hurdles to develop global quality biopharmaceuticals. China's cFDA had made the leap to close the gaps in terms GMP concept, facility and quality standards including data integrity. The regulatory environment change provides the opportunities for companies who are insist doing the right things for patient's benefits that means product quality, patients' safety and efficacy. Zhejiang Teruisi Pharmaceutical Inc. is one of companies, which is insisting on developing global quality biopharmaceutical products for China and global market. We had developed highly similar (physicochemical and biological) biosimilars and high efficacy ADC products that met developed country quality standards such as US/FDA and EU/EMA. We are nearly completing the global cGMP standards (US/FDA, EU/EMA, ICH and cFDA) commercial manufacture facility with 4X 5,000 L capacity, which can provide global CMO services as well as a platform for international collaborations. We will share our development experiences that guarantee product quality by QbD for highly similar biosimilars, innovative New Molecule Entities (ADCs) including new targets ADCs. We will also share the special challenges we had encountered for Biopharmaceutical product development and cGMP manufacture facility built in China.

Session 4: Biomarkers, Translational Research and Precision Medicine

Chairs: Richard Zhao, **Ph.D.,** Professor, University of Maryland School of Medicine, and **Zhifeng Long, Ph.D.,** President, Personal Diagnostix

Richard Y. Zhao, Ph.D.
Professor of Pathology, Microbiology-Immunology and Human Virology
Head, Division of Molecular Pathology
Director, Translational Genomics Laboratory
Director, Molecular Diagnostics Laboratory
University of Maryland School of Medicine
Email: RZhao@som.umaryland.edu

Biography: Dr. Richard Zhao is the former President of the Chinese Biopharmaceutical Association (CBA-USA). Dr. Zhao's expertise is in the area of molecular pathology. His basic science research interests are in the areas of HIV/AIDS, cancer biology, nanoparticle-based single molecule detections, and individualized molecular testing. Dr. Zhao has published over one hundred scientific papers and has served on numerous scientific editorial boards including PLoS ONE, Cell Research, Retrovirology and Cell & Bioscience. He has been invited to give scientific lectures world-wide. Dr. Zhao is at present a leadsperson at the University of Maryland Baltimore on various China collaborative projects.

Zhifeng Long, Ph.D.
President, Personal Diagnostix, Inc.
Phone #: 301-337-8238
E-mail: zlong@diagnostix.com

Biography: Dr. Long is the Founder and President of Personal Diagnostix (PDx), which he founded in 2010. He is also a co-founder of five other biotech companies including American Genetic Testing Co., Interactive Health, and ACC Therapeutics, Inc. Prior to founding PDx, he was the founding vice president of AnGes Inc. During his tenure, AnGes raised $180 million from the Tokyo Stock Exchange and received another $179 million funding from Daichi Pharmaceuticals for the clinical co-development of human hepatocyte growth factor (HGF) for the treatment of peripheral artery disease (PAD) and ischemic heart disease (IHD) in the US and Japan. Dr. Long started his biotech / pharmaceutical professional career in 1987 at Hoffmann-La Roche. He had held senior management positions at Quality Biotech Inc. (QBI, acquired by AppTec, which was later acquired by Wuxi Pharma), Genetics Therapy Inc. (acquired by Sandoz Pharmaceuticals Corp.), Novartis Pharmaceuticals Corp., and AnGes, Inc. Dr. Long was elected to serve as the president of the Chinese Biopharmaceutical Association – USA (CBA), a non-

profit, Washington DC based biopharmaceutical professional organization during 2011-2012. He currently serves at the Board of Directors of CBA.

Baseline for Health

Guo-Liang Yu, Ph.D.
Founder and Chairman
Quantum Health Inc
E-mail: guoliang.yu@crownbio.com

Biography: Dr. Guo-Liang Yu is a venture partner at Orbimed Venture LLC and Founder of Quantum Health Inc., an Internet plus health care management company. He is also the Executive Chairman of Crown Biosicence Inc., a public listed personalized oncology platform company with ~500 employees globally. Dr. Yu co-founded Epitomics Inc., an antibody biotechnology company recently acquired by Abcam at $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years. Dr. Yu's success is driven by his scientific curiosity and a passion to translate scientific discovery to real products. He came from China to pursue advanced training after graduated in biochemistry from Fudan University in 1984. He obtained his Ph.D. in UC Berkeley where he and Dr. Greider discovered telomerase and its mechanism in Dr. Blackburn's lab. Drs. Blackburn and Greider received Nobel Prize in 2009 for their discovery. Dr. Yu then joined Dr. Frederick Ausubel's lab at Harvard to pursue the question how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene. In 1993, instead of continue his academic interests, Dr. Yu became one of the first senior scientists in Human Genome Sciences Inc., when genomics was still in its infancy, identifying human genes for drug discovery. Among several important drug targets he studied, BLys was the first successfully genomic target for the development of a lupus antibody drug Benlysta approved by FDA in 2010. In 1998, Dr. Yu was attracted to identify plant genes with economic value in agriculture and in bio-energy. He was SVP of R&D at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors. Several valuable traits such as enhanced crop yield, disease resistance and drought tolerance were identified. Dr. Yu co-authored 43 peer-reviewed scientific articles that are referenced by the scientific community more than 6000 times. Dr. Yu also co-invented more than 200 patents. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and serves on the boards of several professional organizations including Bayhelix, CABS, National Foundation of Cancer Research, Ray Wu Memorial Foundation, University of Pacific in the US and China. Dr. Yu is generous in coaching young entrepreneurs and involved in founding many start-up companies.

Abstract: Most times, when someone is diagnosed with serious diseases such as cancer or heart disease, it is too late. Although there are many new advances in current biotechnology and medicine, we still face major challenges in treating hundreds kinds of illnesses. We only wish we can predict when and what disease is coming so we can either prepare for it or prevent it. All diseases have underlining molecular mechanism and typically there are early signs of such disease progression. Systematically testing blood at molecular cellular levels over time provides a significant opportunity to find potential risk of disease early. We have developed system to test blood biochemistry using only drops of blood fingertips. The entire system is under the management of advanced IT system.

Optimization of Next Generation Diagnostic Services for Pharmaceutical Development Programs

Arejas J. Uzgiris, Ph.D., Senior Director
Siemens Healthcare
E-mail: arejas.uzgiris@siemens.com

Biography: Arejas J. Uzgiris, Ph.D. is a Senior Director at Siemens Healthcare. He is the head of Companion Diagnostics and Strategic Biomarker R&D in the new Molecular Services organization. His scientific background includes development of next generation sequencing technologies as part of the Human Genome Program; the first pharmacogenetic assay cleared by FDA; and innovative infectious disease and oncology tests implemented for global CDx programs through the Siemens Clinical Laboratory. Dr. Uzgiris received his Doctorate Degree in Chemistry, with a Minor Program in Biotechnology, from the University of Wisconsin, Madison, in 1997.

Transforming Precision Medicine: Opportunities and Challenges in Decoding the Real Genome

Wei Zhou, Ph.D.
Chief Executive Officer, Centrillion Tech, Inc.
Phone #: #: 650-391-8592
E-mail: wzhou@centrilliontech.com

Biography Dr. Wei Zhou is the CEO of Centrillion Tech, a genomics technology company focusing on developing a new generation of technologies for decoding the real genome. Before founding Centrillion, Dr. Zhou was a partner at WSGR, a leading technology law firm. Prior to WSGR, Dr. Zhou was a vice president of intellectual property and advanced technology at Affymetrix where he also served as its first China Country Manager. At Affymetrix, he was credited with building a world class IP portfolio and building Affymetrix' China operation. Dr. Zhou is serving on the board of HYSTA, a non-profit focusing on technology entrepreneurship.

Abstract Genomics is a core technology driving precision medicine innovation and adoption. However, despite a decade of rapid technology evolution, our ability to decode the real genome is still limited. Increasingly, we have realized that the genome is complex and dynamic and current technologies are limited in its ability to decode real genomes. Technology innovations are greatly needed to drive the next phase of growth in the genomics industry and to enable large scale adoption in precision medicine and consumer applications. While genomics applications and market are increasingly global, core genomic technology developments are still extremely expensive and are currently concentrated in few companies. In this talk, I will attempt to summarize a few potential opportunities and challenges in this industry and share my view on industry evolution both in the US and in China.

Session 5: What Scientists and Entrepreneurs in US Should Know

Chairs: Ching-Jey George Chang, Ph.D., Chair, ASQ509 Biomed/Biotech Special Interest Group, and **Steve Chen, J.D., Ph.D.,** Patent Counsel, DSM Nutritional Products LLC.

C.J. George Chang, Ph.D.
ASQ509 Biomed/Biotech Special Interest Group
Phone #: 240-793-8425
E-mail: gchang2008@yahoo.com

Biography: Dr. C.J. George Chang is a veterinarian, veterinary pathologist, and toxicologist by training and a self-trained analytical chemist. He currently serves as a senior pharmacologist at the US FDA Center for Drug Evaluation and Research (CDER), and is responsible for nonclinical review of oncology drug applications. Before joining the Federal workforce, Dr. Chang had worked in pharmaceutical, bioinformatics, contract research, and agrichemical industries. Dr. Chang is the inaugural and current chair for biomed/biotech SIG of the local chapter of American Society for Quality covering DC and Central Maryland (http://www.asq509.org/ht/d/sp/i/31557/pid/31557). He serves on the board of Association for Government Toxicologists (AGT) and the Vice President for Education of FDA White Oak Toastmasters Club. Dr. Chang was a past president of local chapter of Chinese American Professionals Association (CAPADC) and National Taiwan University Alumni Association (NTUAADC). He was a past board member of local Monte Jade Science and Technology Association (MonteJadeDC), National Capital Area of Society of Quality Assurance (NCARSQA), and Chinese Culture and Service Center (CCACC).

Steven Chen, JD, PhD
Patent attorney at DSM Inc.
Phone #: 410-227-6728
E-mail: steven.chen@dsm.com

Biography: Dr. Steven Chen is a Patent Attorney at DSM, Inc., a Dutch-based multinational life sciences and material sciences company. His practice focuses on domestic and foreign patent prosecution, management and enforcement, IP transactions, product clearance, and patent due

diligence. Before joining DSM, Dr. Chen was an attorney at the law firm of Jones Day LLP in New York City. Dr. Chen received his PhD in biology from University of Maryland, his JD from Fordham University Law School, and his BS degree from Fudan University.

Trade Secrets and Economic Espionage: Legal Risks in Advancing Technology between the U.S. and China

Jeremy S. Wu, Ph.D.
Federal Government (retired) and Member of Committee of 100
Phone #: 703-748-2174
E-mail: Jeremy.S.Wu@gmail.com

Biography: Dr. Jeremy S. Wu retired from the U.S. federal government after more than 30 years of public service, having served as the National Ombudsman at the Department of Energy and Civil Rights Director at the U.S. Department of Transportation. He was Senior Advisor and Program Manager to the U.S. Census Bureau, where he was recognized for his innovative work on a nationwide longitudinal data system about the dynamics of American jobs and received the Gold Medal Award from the Department of Commerce. He represented the United States on statistical issues in international food standards development and wheat trade negotiations with China, becoming the first Asian Pacific American career senior executive in the Department of Agriculture in 1997. Jeremy is a member of the Committee of 100, and was Washington Region Co-chair in 2014-2016. He also served three terms as Chair of the Asian American Government Executives Network and received the Stanley Suyat Award for Public Service. Jeremy earned his undergraduate and doctorate degrees in Statistics from the George Washington University, and is currently an adjunct professor at the university.

Abstract: Chinese scientists, technology professionals, and federal government employees in the United States have increasingly become the focus of criminal investigations and prosecutions involving national security, intellectual property theft, and corporate espionage in the United States. In this presentation, Committee of 100 member Jeremy S. Wu will discuss the complex U.S. legal environment, historical context, and geo-political background surrounding some of the more notable cases that have been brought by the government against Chinese American scientists and government employees. This talk is particularly relevant to Chinese American and Asian American federal employees, government contractors, and professionals in the STEM fields. The Committee of 100 is a leadership organization of prominent Chinese Americans in business, government, academia, and the arts. For over 15 years, the Committee of 100 has been actively promoting due process and equal protection in economic espionage cases involving Chinese Americans. Since 2013, C-100 has been leading

educational seminars on the risks and requirements posed by complex U.S. laws on trade secrets, espionage, and export controls. To learn more, please visit: www.committee100.org.

Lin Sun-Hoffman, Ph.D., J.D.
Partner at Liu, Zheng, Chen & Hoffman, LLP
E-mail: lshoffman@ambizlaw.com

Biography: Dr. Lin Sun-Hoffman is currently a founding partner of Law firm Liu, Zheng, Chen & Hoffman based in New York City and Silicon Valley. She has almost 20-year experience in the intellectual property field, including patent preparation and prosecution, due diligence, opinion work, and licensing negotiation and drafting. Dr. Sun-Hoffman held position at United States Patent and Trademark Office (USPTO) as a patent examiner. She also served as managing patent attorney at Celera Genomics, senior patent attorney at Life Technologies Corporation (ABI, now Thermo Fisher). She worked several years as a postdoctoral research fellow with several publications at the NCI, Frederick, Maryland. Dr. Sun-Hoffman served as Chief Advisor for Asia at Biotechnology Industry Organization's (BIO) from 2009-2011. She was the president of Chinese Biopharmaceutical Association from 2008-2009. Currently She serves as vice chair of LES International University-Industry-Government subcommittee, Bay Area Chapter head for Bayhelix Group, Secretary General of US-China Green Energy Council. She is also serving on the PTA executive council of Palo Alto School District, and teaches underprivileged students in rural area Yunnan China every summer. Dr. Sun-Hoffman obtained her J.D. from University of Maryland School of Law; Ph.D. in Biochemistry/Cell and Molecular Biology from the University of Nevada Reno. She is licensed in Maryland and admitted to practice before U.S. Patent and Trademark Office.

Session 6: CBA-SCBA Joint Session - Cancer Therapeutics

Chairs: Li Yang, **Ph.D.,** Senior Investigator & Head, Tumor Microenvironment Section, Laboratory of Cancer Biology and Genetics, NCI, and **Mitchell Ho, Ph.D.,** Senior Investigator, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, NCI

Targeting Myeloid TGF-beta Signaling in Cancer Metastasis

Li Yang, Ph.D., Senior Investigator
National Cancer Institute, NIH
Phone #: 3014965260
E-mail: yangl3@mail.nih.gov

Biography: Dr. Li Yang is a Senior Investigator at the National Cancer Institute (NCI). She received her Ph.D. in the Department of Cancer Biology at Vanderbilt University, under the mentorship of Dr. David Carbone. Her dissertation research focused on COX-2 pathway in tumor progression, immune suppression, and the contribution of host myeloid cells to tumor blood vessel formation. She investigated TGF-β regulation of inflammation and tumor microenvironment during her postdoc research with Dr. Harold Moses. She joined NCI in 2009. Her research program is devoted to understanding the molecular mechanisms underlying tumor-stroma interaction during metastatic process.

Abstract: TGF-β functions as both a tumor suppressor and a tumor promoter. The mechanisms underlying this switch in TGF-β function during tumor progression is not well understood. Studies from our lab demonstrate that epithelial TGF-β signaling possesses potent anti-inflammatory activity. Loss or down-regulation of TGF-β signaling induces the recruitment of Gr-1+CD11b+ immature myeloid cells (iMC) into the tumor microenvironment. Additionally, these iMC are also present in the lungs of tumor bearing mice prior to tumor cell arrival (premetastatic lung). Unexpectedly and strikingly, deletion of TGF-β signaling specifically in the myeloid cells significantly decreased cancer metastasis. The underlying mechanisms involve decreased immune suppression and decreased tumor cell survival in distant site. Our studies suggest that myeloid TGF-β signaling is metastasis- promoting, which is distinct from the tumor suppression effect of TGF-β signaling in epithelial cells, fibroblasts, and some of the T cells. Our research demonstrates that myeloid-specific TGF-β signaling is an essential component of the metastasis-promoting puzzle of TGF-β, and provides mechanistic insight for a cell type specific cancer-targeting strategy.

Novel Antibodies Target Cancer Signaling

Mitchell Ho, Ph.D., Senior Investigator
National Cancer Institute, NIH
Phone #: (301) 451-8727
E-mail: homi@mail.nih.gov

Biography: Dr. Mitchell Ho is Senior Investigator and Chief of the Antibody Therapy Section, Laboratory of Molecular Biology, in the National Cancer Institute (NCI), NIH. His research focuses on the use of antibody engineering technology to advance the development of cancer therapeutics. Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign. He was a postdoctoral fellow with Ira Pastan at the NCI. Dr. Ho is Chair of the NIH Antibody Interest Group, and serves on the Board of Distinguished Advisors for the Antibody Society. Dr. Ho regularly presents at international symposia and is a member of the organizing committees for several major international conferences on therapeutic antibodies. He is also Chair of the Department of Biochemistry in the FAES Graduate School at the NIH.

Abstract: Heparan sulfate proteoglycans (HSPGs) are important modulators of signal transduction pathways during development and disease. However, the role of HSPGs in cancer pathogenesis remains poorly understood. Our lab has pioneered the production of inhibitory antibodies that attack tumor-specific glypicans. These glypicans are cell-surface HSPGs that modulate multiple signaling pathways known to be fundamental in cancer development. We have generated human monoclonal antibodies that have the unique ability to inactivate the Wnt-Yap signaling pathways by binding to cryptic Wnt binding sites on glypican-3 (GPC3). Our Wnt-inhibitory antibodies not only serve as new research tools to investigate the biological interaction of Wnt and GPC3 but also exhibit significant inhibition of GPC3-positive liver-tumor growth in mice. To further enhance the antitumor efficacy, we have constructed chimeric proteins composed of an antibody fragment fused to a pseudomonas toxin. Our immunotoxin causes the regression of liver cancer in mice via dual inhibition of both Wnt-Yap signaling and protein synthesis. Our work established GPC3 as a new therapeutic target for immunotoxins and other antibody-toxin/drug conjugates in liver cancer.

Rationalize Target Combination in Cancer Cells



Ji Luo, Ph.D., Investigator
Center for Cancer Research, National Cancer Institute
Phone #: 301-451-4725
E-mail: ji.luo@nih.gov

Biography: Ji Luo received his B.A. in Natural Sciences from the University of Cambridge, UK in 1998. He completed his Ph.D. training as an HHMI Predoctoral Fellow in the laboratory of Dr. Lewis Cantley at Harvard University, Boston. His Ph.D. research focused on the role of PI 3-kinase in development, diabetes and cancer. Ji Luo undertook his postdoctoral training as an AACR Fellow in the laboratory of Dr. Stephen Elledge at Harvard Medical School, Boston. His postdoctoral research focused on the development of bar-coded shRNA library technologies for genome-wide RNAi synthetic lethal analysis in cancer cells.

Abstract: Combination therapy is the future of cancer treatment. A major challenge is how to rationally identify efficacious drug and target combinations from the myriads of available compounds and druggable targets. We have used both matrix drug screen and siRNA combinatorial screens to identify both drug combinations and target combinations that might be useful for the treatment of solid tumors with mutations in the KRAS oncogene. Our approach represents a rational method for the discovery of new modality for cancer treatment.

Special Evening Presentation

Made in China in 2025

Xiang，Xianshao 上海耐利生化设备有限公司首席执行官
CEO, Shanghai Naili Biochemistry Equipment Co., Ltd.
758 Fuyong Road Songjiang District Shanghai 201600P.R.China
Phone: +862133521182
Mobile: +86 138 1668 2345
E-mail: xxs@NaiLii.com http:www.NaiLii.com

Biography: Expert in integrated design, fabrication and installation of equipment and process in biopharmaceutical manufacturing. Principal investigator of integrated cell culture equipment and process. Lead of 2000L process and technology development of microcarrier suspension cell culture. Principal investigator of National 12th 5-year 863 project – large scale animal cell culture bioreactor key process, equipment and technology development and commercial production.

美国华人生物医药科技协会（CBA）简介

美国华人生物医药科技协会(Chinese Biopharmaceutical Association，简称 CBA)是美国最大的中美专业协会之一。CBA 创建于 1995 年，是一家独立的、非官方的、非盈利的专业组织。CBA 由选举产生的董事会，董事会顾问和执行委员会领导。CBA 是由美国国税局根据国内税收法典“第 501（c）（3）条款”认证的免税团体。

CBA 的首要宗旨是促进美国和中国生物制药界的专业人士之间的各个知识层面上的全面交流，培育生物制药公司和研究机构合作成长和事业成功的环境。CBA 总部设在美国马里兰州，目前拥有 3000 多名注册个人会员，以及超过 60 个机构成员。大部分的 CBA 成员都是来自生物制药公司，大学，研究机构和政府机构。超过 80％的 CBA 成员具有博士学位。除了来自美国的成员外，CBA 也有成员居住在中国，欧洲，加拿大，澳大利亚，新加坡和日本。

自成立以来，CBA 已经对中国和美国生物制药行业之间的合作进行了积极推动作用。CBA 每年都自主组织或与其他团体共同举办一些特别设计的讲习班，研讨会，专题会议和社交联谊活动。 CBA 最有影响力的事件是其每年举办一次的年会。每年的年会都吸引数百成千的参加者，许多国际知名的科学家，商界领袖，以及美国和中国高级政府官员出席过 CBA 的年会，并在年会上发言。其中的杰出的演讲者包括诺贝尔奖获得者：夏普勒斯·巴里博士（Drs. K Barry Sharpless 2001），阿夫拉姆•赫什科（Avram Hershko ，2004 年），吕克·蒙塔尼（Luc Montagnier ，2008 年）和彼得·阿格雷（Peter Agre，2003 年）；以及中国的卫生部长陈竺博士，生物技术工业组织（BIO）总裁兼首席执行官詹姆斯·C·格林伍德先生，人类基因组公司生物董事长兼首席执行官托马斯·沃特金斯先生（Mr. Thomas Watkins），Glycomimetics 的首席执行官和现任生物技术工业组织（BIO）总裁雷切尔·金女（Mrs. Rachel King）；还有许多美国和中国的科学院院士包括保罗·希梅尔博士（Drs. Paul Schimmel），罗伯特·C·加洛，（Robert C. Gallo），伯纳德·罗伊兹曼（Bernard Roizman），E.阿尔伯特里斯（E. Albert Reece），赵国屏（Guoping Zhao), 王存玉 (Cun-Yu Wang), and 陈凯先 (Kaixian Chen)。

在过去的十年中，中国的生物制药行业获得巨大的增长，其呈现的各种优势已经吸引了许多全球性制药公司中国。为了促进中国和美国的生物制药产业之间的合作，CBA 制定了策略，加强连接中美生物制药行业的活动。除了在美国举办的专业会议，CBA 也将其活动扩展到中国，在上海，广州，青岛, 连云港分别成功举办了第 13 届，第 14 届, 第 17 届和第 20 届会议。CBA 及其举办的活动已被一些著名的科学和商业杂志及新闻媒体，如自然，科学，汤森路透社，公关通讯社，新华社，BioPorfolio，国际生物制品杂志。在马里兰州，CBA 已经协助安排并参加了 2011 年州长 Martin O'Malley 的贸易代表团访问中国的活动。CBA 和广州经济技术开发区于 2013 年 6 月发起并实施了“中美生物医药之桥”的特殊合项目，进一步促进美国和中国之间人才和项目的交流。

CBA 于 2016 年 2 月 27 日和 6 月 27 日分别成功举行了 20 周年新年晚会和 CBA 第 20 届年会并在会上展望规划了 2016 年的工作。其中的杰出的演讲者包括诺贝尔奖获得者：夏普勒斯·巴里博士（Dr. K. Barry Sharpless）及享有"一氧化氮之父" 美誉的诺贝尔奖获得者裴瑞德·穆拉德博士 (Dr. Ferid Murad).

CBA 成功归因于 CBA 会员相信 CBA 的使命的积极参与。如今，全球生物制药行业和医疗的不断发展和壮大，特别是在中国和亚太地区， CBA 在新的一年里将迎接新的机遇与挑战。

CBA Brilliant Achievement Award Recipients

The CBA Brilliant Achievement Award was established in 2003 to honor outstanding individuals who have made seminal contributions to science, technology, or business development in the biopharmaceutical fields; whose vision has moved medicine in new directions; and who has been actively involved in building collaborative efforts internationally to advance medical fields. The Award also aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

Dr. Bahija Jallal, Executive Vice President of AstraZeneca and Head of MedImmune (2016)

Dr. Ge Li, CEO and Chairman of Board of Directors, WuXi AppTec (2016)

Dr. Zhu Chen, Vice-Chairman, 12th Standing Committee of the NPC; Chairman, 15th Chinese Peasants and Workers Democratic Party, Member of Chinese Academy of Sciences， Foreign member of the United States National Academy of Sciences (2015)

Barry K. Sharpless, Ph.D., 2001 Nobel Laureate for Chemistry, member of the United States National Academy of Sciences, W. M. Keck Professor of Chemistry at The Scripps Research Institute (2015)

Chen Kaixian, Ph.D., Member of Chinese Academy of Sciences
Professor， Shanghai Institute of Materia Medica, Chinese Academy of Sciences
2015 CBA Lifetime Achievement Award

Piaoyang Sun, Ph.D., Chairmen, Jiangsu Hengrui Medicine CO, LTD,
CBA Outstanding Contribution Award (2015)

Mr. Yanghao Chen, Deputy Director, Guangdong Overseas Chinese Affairs Office, CBA Extraordinary Support Award (2015)

James F. Young, Ph.D., Chairman, Board of Directors, Novavax, Inc. (2014)

James L. Hughes, MBA, Vice President, Chief Enterprise Economic Development Officer, President, UM Health Sciences Research Park Corporation, University of Maryland Baltimore (2013)

Bernard Roizman Sc.D., Joseph Regenstein Distinguished Service Professor, University of Chicago (2012)

Ren Jinsheng, Founder, Chairman, and Chief Executive Officer, Simcere Pharmaceutical Group (2012)

Jonathan M. Rothberg, Ph.D., Founder, CEO and Chairman, Ion Torrent Corporation (2011)

Thomas Watkins, President and CEO, Human Genome Sciences Inc. (2011)

Eric Green, M.D., Ph.D., Director, National Human Genome Research Institute, National Institutes of Health (2010)
Gabriel Leung, President, Pharmaceuticals Business, OSI Pharmaceuticals (2010)

Luc Montagnier, M.D., 2008 Nobel Laureate for Physiology and Medicine, Emeritus Professor, C.N.R.S. President of the World Foundation for AIDS Research and Prevention (2009)

Robert C. Gallo, M.D., Director and Professor, Institute of Human Virology of the University of Maryland School of Medicine (2009)

Nanshan Zhong M.D., President of China Medical Society, Member of Chinese Academy of Engineering (2009)

Zhong Nan-shan, M.D., 中华医学会会长, 中国工程院院士 (2009)

James C. Greenwood, President and CEO, Biotechnology Industry Organization (BIO) (2008)

Jing Lou, M.D., Ph.D., CEO, 3SBio Inc. (2007)

Paul Schimmel, Ph. D., Ernest and Jean Hahn Professor, The Scripps Research Institute (2006)

Frederick Frank, Ph.D., Vice Chairman and Director, Lehman Brothers Inc. (2005)

Nancy T. Chang, Ph.D., President & CEO, Tanox, Inc. (2004)

Kenneth Fong, Ph.D., Chairman, KENSON Ventures (2003)

CBA Outstanding Service Award Recipients

The CBA Outstanding Service Award was established in 2003 to honor individuals who have made significant contributions to CBA:

Richard Zhao, Ph.D., Professor, University of Maryland School of Medicine (2016)

Zhifeng Long, Ph.D., President, Peronsal Diagnostix (2015)

Sujuan Ba, Ph.D., Chief Operating Officer, National Foundation for Cancer Research (2014)

Yifan Zhai, M.D., Ph.D., CEO & President, Healthquest Pharma (2013)

Lin Sun-Hoffman, J.D., Ph.D., President, Sun-Hoffman Consulting (2012)

Yuling Li, Ph.D., Fellow, Process Biochemistry, MedImmune (2011)

Dajun Yang, M.D., Ph.D., Co-Founder, Chairman & CEO, Ascentage Pharma Group Corp. (2010)

Yingxian Xiao, Ph.D., Associate professor, Georgetown University School of Medicine (2008)

Jian Ni, M.D., Ph.D., CEO & Chief Scientist, Human Antibodomics Inc. (2007)

Wei-Wu He, Ph.D., Founder, Emerging Technology Partners LLC (2006)

Sun Lu, Ph.D., Executive Vice President, GeneCopoeia, Inc. (2005)

Patrick Y. Lu, Ph.D., Co-Founder, Executive VP, Intradigm Corporation (2004)

Guo-Liang Yu, Ph.D., Co-Founder, Formerly President & CEO, Epitomics Inc. (2003); now Chairman of Quantum Health Inc**.**

CBA Annual Conferences

(1996 – 2016)

Since its inception in 1995, CBA has organized and/or sponsored many activities to reach its goals. It has hosted a number of Biopharmaceutical delegations from China, and organized seminar series on biopharmaceutical research and development, patent law, intellectual property protection, and government regulations. CBA has also organized and co-sponsored international conferences, workshop delegations to introduce to colleagues in China the latest technology breakthroughs in biotechnology and pharmaceutical industry.

21st Annual Conference	**Biopharm US-China: Accelerating Global Development and Commercialization through Partnerships** June 11, 2016, MedImmune Conference Center, Gaithersburg, Maryland
20th Annual Conference	**Globalization of Biopharmaceutical Development and Commercialization – Emerging Market Opportunities** June 28-30, 2015, LianYunGang HaiZhouWan Conference Center, LianYunGang, Jiangsu, P.R. China
19th Annual Conference	**Advancement and Global Opportunities in Innovative Biopharmaceutical Development** June 21, 2014, USM Shady Grove Conference Center, Rockville, Maryland
18th Annual Conference	**Global Partnership in Biopharmaceutics and Translational Medicine** June 15, 2013, USM Shady Grove Conference Center, Rockville, Maryland
17th Annual Conference	**Emerging Market for Biopharmaceutics in Asia: Opportunities and Challenges** July 2-3, 2012, Shangri-La Hotel, Qingdao, P.R. China
16th Annual Conference	**From Personal Genomes to Translational Medicine** June 26, 2010, USM Shady Grove Conference Center, Rockville, Maryland
15th Annual Conference	**Biopharmaceutical Medicines: Development and Commercialization without Boarders** June 12 – 13, 2010, USM Shady Grove Conference Center, Rockville, Maryland

14th Annual Conference	**Biopharmaceutical Innovation and Commercialization** June 18 – 20, 2009, Guangzhou Baiyun International Convention Center, Guangzhou, P.R. China
13th Annual Conference	**Biotechnology Innovation and Sustainable Development** May 28 – 30, 2008, Shanghai International Convention Center, Shanghai, P.R. China
12th Annual Conference	**Dynamic Biopharmaceutical Development: from Discovery to Commercialization** June 2 – 3, 2007, USM Shady Grove Conference Center, Rockville, Maryland
11th Annual Conference	**Dynamic Changes in the Biopharmaceutical Industry: Challenges and Opportunities** May 13 – 14, 2006, USM Shady Grove Conference Center, Rockville, Maryland
10th Annual Conference	**Biopharmaceutical Globalization: Strategies and Perspectives** June 18 – 19, 2005, USM Shady Grove Conference Center, Rockville, Maryland
9th Annual Conference	**Trends in Biotechnology: New Strategies and Perspectives** June 12 – 13, 2004, USM Shady Grove Conference Center, Rockville, Maryland
8th Annual Conference	**Biotechnology & Pharmaceutical Industry: Technology Platforms and Business Models** October 4-5, 2003, USM Shady Grove Conference Center, Rockville, Maryland
7th Annual Conference	**Drug Development in USA and China: Impact of Human Genome Project and World Trade Organization** April 6-7, 2002, USM Shady Grove Conference Center, Rockville, Maryland
6th Annual Conference	**Biotechnology: From Research to Commercialization in Life Science Industry.** April 7-8, 2001, Washingtonian Marriott, Gaithersburg, Maryland
5th Annual Conference	**Biotechnology: Genomics in the Information Age** June 17-18, 2000, Washingtonian Marriott, Gaithersburg, Maryland

4th Annual Conference	**Biotechnology, Genomics and Beyond** April 3-4, 1999, Washingtonian Marriott, Gaithersburg, Maryland
3rd Annual Conference	**Biotechnology: From USA to China** April 4-5, 1998, Washingtonian Marriott, Gaithersburg, Maryland
2nd Annual Conference	**Biotechnology: From Benchtop to Marketplace** April 5, 1997, J.W. Marriott, Washington DC
1st Annual Conference	**Biotechnology: Today and Tomorrow.** April 6, 1996, J.W. Marriott, Washington DC

CBA Elected Presidents (1996 – 2016)

1996 – 1997	*Guoliang Yu*
1997 – 1999	*Patrick Lu*
1999 – 2000	*Sun Lu*
2000 – 2001	*Wei Wu He*
2001 – 2003	*Jian Ni*
2003 – 2004	*Yingxian Xiao*
2004 – 2005	*Roxanne Duan*
2005 – 2006	*Dajun Yang*
2006 – 2007	*Dan Zhang*
2007 – 2008	*Yuling Li*
2008 – 2009	*Lin Sun-Hoffman*
2009 – 2010	*Yifan Zhai*
2010 -- 2011	*Sujuan Ba*
2011 – 2012	*Zhifeng Long*
2012 – 2013	*Richard Zhao*
2013 – 2014	*Ping Chen*
2014 – 2015	*Ziping Wei*
2015 - 2016	*Shou-Bai Chao*

CBA Board of Directors

(2015-2017)

Qiao Y. Bobo
George Chang
Shou-Bai Chao
Kai Chen
Ping Chen
Steve Chen
Zhenxia Chen
Yali Fu
Xu-Rong Jiang
Feiyan Jin
Alex Lai
Shoupeng Lai
Kening Li
Zhifeng Long
Xiaobin Lu
Helen Mao
Jian Ni
Linda Powers
Peter Qian
Wuzhou Wan
Edward Wang
Ziping Wei
Jean Z. Xiao
Yingxian Xiao
Dong Xie
Chunzhang Yang
Yifan Zhai
Jifeng Zhang
Monica Y. Zhang
Richard Y. Zhao
Min Zhu

CBA Advisory Board

Chair: Guoliang Yu

Sujuan Ba
Roxanne Duan
Lin Sun Hoffman
Wei Wu He
Yuling Li
Sun Lu
Dajun Yang
Hongjun Yang
Dan Zhang
Patrick Lu

Scientific Advisor to the BOD and Lifetime Member

Cun-Yu Wang, D.D.S., Ph.D.

Member of the Institute of Medicine, National Academies of United States
Foreign Member of the Chinese Academy of Engineering
Professor and Associate Dean for Graduate Studies
Chair of the Division of Oral Biology & Medicine
Dr. No-Hee Park Endowed Chair in Dentistry
University of California at Los Angeles

CBA Officers

CBA Executive Committee

(June 2015 – June 2016)

President: *Shou-Bai Chao, Ph.D.*

President-Elect: *Xu-Rong Jiang, M.D., Ph.D.*

Immediate Past President: *Ziping Wei, Ph.D.*

General Secretary, CBA Board of Directors

Shoupeng Lai, Ph.D.

Treasurer: *Feiyan Jin, Ph.D.*

General Counsel: *Kening Li, Ph.D., J.D.*

VP of Fundraising
Min Zhu, Ph.D.

VP of Execution
Yingxian Xiao, Ph.D.

VP of Outreach
Peter Qian, Ph.D.

VP of Project Management
Alex Lai, Ph.D.

VP of Public Relations
Chunzhang Yang, Ph.D.

VP of Science and Technology
Yali Fu, Ph.D.

VP of Membership
Xiaobin Lu, Ph.D.

VP of Marketing and Communications
Monica Zhang, MA

VP of Logistics
Edward Wang, Ph.D.

VP of Event Coordination
Wuzhou Wan, Ph.D.

CBA Functional Committees (June 2015 – June 2016)

Membership Committee:
Chair: Xiaobin Lu
Members: Xiaomeng Zhang, Monica Zhang

Fundraising Committee:
Chair: Min Zhu
Members: Xu-Rong Jiang, Kun Yao, Jifeng Zhang, Helen Mao, Ziping Wei, Shou-Bai Chao

Website and E-newsletter Committee:
Chair: Monica Zhang
Members: Jingya Wang, Leiyun Weng, Yebin Zhou, Zhenxia Chen, Bob Zhang

Finance Committee:
Chair: Feiyan Jin
Members: Min Zhu, Yali Fu, Limin Zhang

Public Relations
Chairs: Chunzhang Yang
Members: Zhenxia Chen, George Chang, Yun Zhang, Yingxian Xiao, Xiaomeng Zhang

Career Workshop Committee:
Chair: Chunzhang Yang
Members: George Chang, Li Li, Feiyan Jin, Xiaobin Lu, Xiaomeng Zhang

Annual Gala Committee:
Chairs: Feiyan Jin
Members: Edward Wang, Xiaomeng Zhang, Xiaobin Lu, Peter Qian

Event Logistics Committee:
Chairs: Edward Wang; Co-chair: Peter Qian
Members: Min Zhu, Limin Zhang, Xiaomeng Zhang, Xiaobin Lu, Heng Xie

Project Committee:
Chairs: Ziping Wei; Co-chair: Alex Lai
Members: Shou-Bai Chao, Ping Chen, Richard Zhao, Yingxian Xiao

Scientific and Academic Committee:
Chairs: Yingxian Xiao; Co-chair: Yali Fu
Members: Heng Xie, Jian Zhang, Richard Zhao

The Organizing Committee of the CBA 21st Annual Conference

Chairman: Xu-Rong Jiang

Qiao Y Bobo	*George Chang*	*Shou-Bai Chao*	*Ping Chen*
Steve Chen	*Zhenxia Chen*	*Chunshan Deng*	*Yali Fu*
Lin Sun-Hoffman	*Feiyan Jin*	*Kening Li*	*Li Li*
Yuling Li	*Zhifeng Long*	*Xiaobin Lu*	*Helen Mao*
Jian Ni	*Peter Qian*	*Dong Shen*	*Edward Wang*
Jingya Wang	*Ziping Wei*	*Yingxian Xiao*	*Heng Xie*
Chunzhang Yang	*Dajun Yang*	*Kun Yao*	*Yifan Zhai*
Dan Zhang	*Limin Zhang*	*Monica Yun Zhang*	*Monica Yun Zhang*
Xiaomeng Zhang	*Richard Zhao*	*Min Zhu*	

Functional Groups of 21st Annual Conference

1. Fundraising Team: *(Chair: Min Zhu)* • *Kun Yao* • *Ziping Wei* • *Jifeng Zhang* • *Michael Huang* • *All members*	**2. VIP Invitation Team:** *(Chair: Yingxian Xiao)* • *Richard Zhao* • *Shou-Bai Chao* • *Xu-Rong Jiang* • *All members*
3. Conference Program Team: *(Co-chair: Xu-Rong Jiang & Shou-Bai Chao)* • *Dang Zhang* • *Qiao Bobo*	**4. Registration Team:** *(Chair: Xiaobin Lu)* • *Min Zhu* • *Xiaomeng Zhang* • *Paula Lei*

• *Yingxian Xiao* • *Yuling Li* • *Ziping Wei* • *Richard Zhao* • *Zhifeng Long* • *George Chang* • *Steve Chen* • *Yali Fu* • *Min Zhu* • *Xiaomeng Zhang*	• *Xia Luo*
5. Public Relation Team: *(Chair: Monica Zhang)* • *Jingya Wang* • *Xiaobin Lu* • *Zhenxia Chen* • *Leiyun Weng* • *Yebin Zhou*	**6. Conference Logistic Team:** *(Chair: Peter Qian)* • *Min Zhu* • *Edward Wang* • *Xiaomeng Zhang* • *Limin Zhang* • *Jasmine Wang*
7. Booth and Exhibition Team: *(Chair: Min Zhu)* • *Edward Wang* • *Fan Yang* • *Jing Zhang* • *Qinghua Zhao*	**8. Special Reception Team:** *(Chair: Peter Qian)* • *Edward Wang* • *Volunteers*

CBA Sponsored & Organized Local and International Conferences, Career Development and Educational Workshops and Other Activities (2010 – 2016):

May 3, 2016	Attended the Szent-Gyorgyi Prize Award Ceremony Honoring Dr. Mary-Claire King, PhD. Networking with prominent people in biomedical fields and invited them to CBA annual meeting for collaboration opportunities in Montgomery County.
April 30, 2016	Held the "2016 Career Development Workshop", over 160 attendees and invited Min Zhu, Timothy Schofield, Sam Hsien-Cheng Chang, Esq, Richard W. Chang, Esq, Steven Chen and George Chang gave speeches, and encouraged younger professionals to develop their own career path. HR show cases were conducted by Medimmune, Novavax, GSK and NextCure.
April 18, 2016	Participated in the BioHealth Capital Region Forum, including health care professionals, CEOs, NIH director, and Governors of Maryland and Virginia. The forum was hosted by MedImmune.
April 11, 2016	Participated in Chinese Investment in biopharmaceutical industry event organized by a delegation from Shanghai, China. Dr. Qiyu Qiu, the fund manager in Shanghai hosted the event.
February 29, 2016	Chinese Embassy in DC invited CBA to attend a face to face technology forum with a delegation from the Ministry of Science and Technology, led by Minister Zhigang Wang. The theme of the discussion forum is “Driven by Innovation, Led by Science & Technology”.
February 27, 2016	Successfully held CBA New Year Gala, more than 200 guests attended the event, including Dr. Ferid Murad, 1998 Nobel Laureate in Medicine, and Mr. John Wobensmith, Secretary of State of Maryland. Reported the status of CBA in 2015 and announced plan for the year of 2016.
January 9, 2016	Hosted a delegation from Yunnan Qiao Ban, China. CBA and YNQB explored future collaboration opportunities, and YNQB invited CBA leaders to visit Yunnan in June 2016.
December 1, 2015	Hosted a delegation of senior leaders from Taikang Life Insurance, China. CBA and Taikang leaders explored future collaboration opportunities, including jointly establishing symposium/forum in China.

November 23, 2015	CBA hosted a delegation of biopharmaceutical leaders from Simcere and BioSciKin. CBA also organized a lab tour as well as bio-manufacture facility tour in MedImmune.
October 24, 2015	Board of Directors and Executive Committee Leadership Retreat, The Bolger Conference Center, Potomac, Maryland
October 22, 2015	CBA hosted a group of 17 delegation from CFDA, most of them are reviewers and managers. A F2F round-table discussion meeting was held followed by a dinner event.
September 23, 2015	Attended the "2015 high-end talent overseas hi-tech bioforum" in Chengdu, Sichuan, China. Strengthened the collaboration with several high tech parks in Sichuan.
September 6, 2015	Annual members picnic co-organized with CSSA in Cabin John Regional Park, MD.
July 17, 2015	Hosted a meeting with a Jiangsu delegation led by Simcere and other biopharmaceutical leaders and Montgomery County Officials at the Germantown Innovation Center for unique collaboration opportunities of bio-companies in Montgomery county.
July 3-10, 2015	Participated in the post-conference project fairs in Changzhou, Gaochun, and Nanjing, Jiangsu, China.
July 1-3, 2015	Established new strategic collaboration with Nanjing Qiao Ban, Jiangsu Qiao Ban and SinoBioWay.
June 28-30, 2015	Successfully held the 20th CBA Annual Conference entitled "Opportunities in Emerging Markets for Biopharmaceutical Development and Commercialization" in Lian Yun Gang, Jiangsu, China. Over 500 attendees, about 30 sponsors including Keynote speaker Dr. Barry K. Sharpless, 2001 Nobel Laureate in Chemistry.
June 26-28, 2015	Successfully held 2015 Hefei International Symposium on Bio-Med Innovation and Entrepreneurship & CBA 20th Anniversary Conference in Hefei Chaohu Economic Development Zone, Anhui, China.
June 8-12, 2015	CBA sponsored MD Governor's trade trip to China and agreed on long term strategic collaborations

June 1, 2015	Coordinated with Bradley Gillenwater of Maryland State Department of Business & Economic Development to hold a very successful state evening dinner event hosted by new Governor Larry Hogan and his wife. CBA was one of the sponsors for this event. Several Chinese biopharma companies started real processes to start their operation in Maryland and Montgomery County.
April 29, 2015	Attended the Szent-Gyorgyi Prize Award Ceremony Honoring Dr. Frederich W. Alt. Networking with prominent people in biomedical fields and invited them to CBA annual meeting for collaboration opportunities in Montgomery County.
April 25, 2015	Hosted a special meeting with the Delegation from Xiuzhou district of Jiaxin county from HangZhou province. Introduced the advantages of establishing biopharmaceutical collaboration with Montgomery County.
April 25, 2015	Held the "2015 Career Development Workshop", over 100 attendees and invited LCDR Qiao Yu Bobo, Wanjun Chen, Samuel Tinsing Mok, CIA, CGFM; Milos Dokmanovic, Kun Yao, gave speeches, and encouraged younger professionals to develop their own career path.
April 12, 2015	Participated in the first innovation and investment affairs by UCTID (Center for U-China Technology, Innovation & Development). There were representatives from China tech parks such as TEDA (Tianjin), Ningbo and VC from China, Silicon Valley (TEEC Angel Fund, TAF), New York, and DC.
March 25, 2015	Participated in Chinese Investment in Maryland Showcase event organized by Maryland Department of Business & Economic Development. CBA was one of sponsors for this event. It was a very successful event, many highly valuable Chinese companies came and visit Maryland， showed their interests to invest in Maryland (attachment 1)
March 11-14, 2015	Visited Lianyungang (LYG) and hold a formal preparation meeting the CBA 20th annual meeting. The CBA team also visited Anhui Chaohu, decided to invite the Secretary of the State to join the event, strengthen the collaboration of Maryland and Anhui as Sister States of 30 years.
February 5, 2015	Held the preparation meeting with JSQB and LYG for the 20th annual conference on June 29-30th. Visited Chaohu, Anhui for potential collaboration to hold a celebration event for CBA in June 27th.

January 24, 2015	Successfully held CBA new year gala, more than 200 guests attended the event. Reported the status of CBA in 2014 and announced the CBA plan for the year of 2015.
December 23, 2014	Visited FuoShan high-tech bio-park, and strengthened the collaboration.
Dec. 21-22, 2014	Attended the Chongqing Bioforum and introduce the CBA projects and presenting the opportunities in Montgomery county as the Biocapital in USA
November 5-7, 2014	Attended 2014 Zhejiang Hangzhou International Human Resources Exchange and Cooperation Conference, and participated in project fair.
October 19-22, 2014	Attended the "2014 high-end talent overseas hi-tech bioforum" in Chengdu, Sichuan, China. Strengthened the collaboration with several high tech parks in Sichuan.
October 13, 2014	Held discussion meeting with "Chinese entrepreneurs policy advisory report group". The report group was from the Chinese State Council Overseas Chinese Affairs Office of Science and Technology Division of the economy, the National Economic Development for Macroeconomic Research, and the National Department of International Cooperation.
October 9, 2014	Held a meeting with Suzhou Associations of Sciences and Technology, and introduced unique development opportunities of bio-companies in Montgomery County.
Sept. 22-26, 2014	Attended the "International Conference for Science and Technology Exchanges, Collaboration and Development" in Haimen, Jiangsu. Visited high-tech parks in several cities including Taizhou and Nanjing.
September 2, 2014	Met with the Vice Governor of Jiangsu Province and the director of Overseas Chinese Affairs Office of Jiangsu, and obtained the support of province resources to support the 20th CBA annual meeting in Jiangsu.
August 31, 2014	Annual picnic co-organized with CAST-DC together with 9 more professional organizations in Cabin John Regional Park, MD.
July 27–Aug 1, 2014	Visited Sichuan Guang Yuan, signed strategic agreement of collaboration. Introduced Montgomery County to the Guang Yuan traditional Chinese medicine industry.

July 21-23, 2014	Participated in the 6th Professional Association of Overseas Chinese joint meeting. Introduced the special advantages of Montgomery county in biopharmaceuticals. Signed the first intentional agreement with Jiangsu Overseas Chinese Office to jointly hold the 20th CBA annual meeting.
June 21, 2014	Successfully held the 19th CBA Annual Conference titled "Advancement and Global Opportunities in Innovative Biopharmaceutical Development". Over 500 attendees, about 30 sponsors including Montgomery County, Executive Ike Legget attended the dinner banquet sponsored by CFLD and gave a speech.
June 7-10, 2014	Attended the 12th Asian Oversea Chinese Entrepreneurs Conference, Signed strategic Collaboration Agreement with Lenovo Investment Group, which is the first time for CBA to establish strategic collaboration with an investment group
June 4-5, 2014	Visited HangZhou High Tech Park and discussed potential collaboration in the future
May 21-22, 2014	Visited Guangzhou Economic Development Zone and Foshan High-Tech Park, presented CBA projects for collaboration
May 19, 2014	Visited Huzhou High Tech Park, established basis for future collaboration
May 20, 2014	CBA-Shanghai Jiaotong University and Fengxian District Bioforum
May 1, 2014	Attended the Szent-Gyorgyi Prize Award Ceremony Honoring James P. Allison. Networking with prominent people in biomedical fields and inviting them to CBA annual meeting for collaboration opportunities in Montgomery County.
April 27, 2014	Held the "2014 Career Development Workshop", about 200 in attendance and invited Dr. Yigong Shi, Member of the Chinese Academy of Sciences. Meeting with Renbin Zhao, Director of Discovery Biology from China for Potential local opportunities
April 23, 2014	CBA met with TopAlliance to follow up their business settlement in Montgomery County. TopAlliance signed a 5 year contract of office lease valued at about half million us dollars. And they plan to invest 1 million a year for five years here and hire up to 10 peoples. Their new office location: 9430 Key West, Rockville, MD 20850

April 4, 2014	CBA met with General Manager Zhang Jiannan and his assistant Mr. Zhu Ning from Nanjin Jian Ye district. Discuss further collaboration.
March 4, 2014，	Met with a group of high tech park management personals of Zhongguancun delegation from Beijing in Virginia in the office of Triway International Group.
March 2, 2014	Met with Mr. Li Yingshun, CEO, Da An Technology in Guangzhou. Discussion their investments on the project for Dr. Kangyan Du.
Feb. 22, 2014	Washington Fudan University Alumni Association and several other Alumni Association collaborated for a new year Gala for Ph.D students and Post Doctors. Ziping gave a talk to introduce the CBA and the opportunities in Montgomery County.
Feb. 5, 2014	Met with two biotech companies from China for setting up business in Montgomery County TopAlliance BioSciences, Suzhou WuJiang, Tech. Incubation Park, Suzhou China 215200. Destiny BIO, 781 Cailum Road, suite 1205, PuDong, Shanghai China 201203
Jan. 12-13, 2014	Met with investment business people from Shanxi China to discuss and attract them to invest in biotech in Montgomery county.
Jan. 11, 2014	CBA 2014 New Year Gala with 230 people attending: presenting CBA 2013 achievement and plan for 2014. Networking
Jan. 5, 2014.1.5	CBA attended the “Chinese Americans for Ike Leggett" fundraising
Oct. 23-24, 2013	CBA visited Beijing, Zhong Guancun, introducing CBA activates and also introducing the Montgomery county as the Bio-capital in USA
Oct. 22, 2013	Visited Jiaxing International Bio-tech Park which is a high-tech industrial park jointly developed by Shanghai Pharm Valley Corp. and BDF Bio-tech (Shanghai) Inc. Introducing CBA, also introducing opportunities at Montgomery County as the Bio-Capital in USA
Oct. 21, 2013	Visited Shanghai Jiao Tong University and meeting with the leaders in the University and layout plan for holding joint biform in May of 2014, at the same time promoting BioHealth Innovation Inc.
Dec. 18-19, 2013	CBA Delegation to Guangzhou Convention of Overseas Chinese Scholars in Science and Technology (GZ OCS Convention): introducing the projects and attracting potential funding to support the projects. This includes

	introduction of the Novavax project and other local companies (Personal Diagnostix, Inc, etc.) to China
Nov. 29, 2013	Started application for Guangzhou Program and start to organize CBA Delegation to GZ OCS Convention
Nov.22-24, 2013	Met with Guangzhou delegation at CBA office, taking them to visit Novavax, Origine , University of Maryland. Holding project meeting with the delegation and the project leaders introduced their projects to the delegation
Oct. 21-23, 2013	The CBA delegation attended the "2013 high-end talent overseas hi-tech biform" in Sichuan, China.
Sept. 17-24, 2013	Joined the County Executive's China mission trip from Sept. 15 to 25, visiting Shanghai, Xi'an and Beijing. CBA signed the collaboration agreement with the Beijing based China Fortune Land Development (CFLD), the CFLD committed to investing into the Rockville-based public-private partnership, BioHealth Innovation, Inc. (BHI)
Sept. 21, 2013	During the county mission trip, Todd Chappell of BHI visited Shanghai Jiao Tong University for further discussion of potential collaboration
Sept. 11-13, 2013	Attended 2013 China (Jiangsu) international exchanges and cooperation in intellectual talent Technology Conference. Introducing the collaboration opportunities in Montgomery county
Aug. 20, 2013	Met with Richard Bendis and Todd Chappell of BHI, introducing Mr. Tao, the principal of Shanghai Jiao Tong University, for potential collaboration.
Aug. 12, 2013	Visited Nanjing Jianye district and discuss for further collaboration, introducing the opportunities in Montgomery county
July 30, 2013	Met with Lily QI & Chairman Wenxue Wang and his team in Montgomery County Gov for collaboration plan between Montgomery county & CFLD
July 25-26, 2013	Attended the ChongQing Bioforum and introduce the CBA projects and presenting the opportunities in Montgomery county as the Biocapital in USA
July 23, 2013	CBA board members joined the CBA Guangzhou Office Opening Ceremony: (1) hold a ceremony; (2) visit bio-island; (3) visit GDD; (4) a meeting with GDD officials; and (5) a meeting with OCAO Officials

July 17-18, 2013	CBA, CFLD and Gu-An County/jointly hold a biform "China Industrial Dream: a new pattern of China-US biological medicine collaboration" in China.
June 20, 2013	Met to discuss how CBA can help and participate in the county's mission trip to China
June 15, 2013	18th CBA Annual Conference held in Maryland.
June 7, 2013	Met with the delegation from Guangzhou high tech development zone, signing strategic collaboration agreement with GuangDong delegation in Boston
May 28, 2013	Attended BHI and CBA meeting: Todd introduced his work as an Entrepreneur-in-Residence and discussed the possible collaboration mechanisms with CBA team.
May 1, 2013	Attended China Mission Trip Briefing Meeting organized by county executive office,
April 23-26, 2013	CBA delegation visited the Nanjin JianYe district in China, discussed and confirmed that the delegation of Nanjin JianYe district will attend CBA annual meeting
April 19-21, 2013	Visited Sichuan Meishan Economic Development Zone, discussed and confirmed Meishan delegation's attendence to CBA annual meeting
March 10, 2013	CBA participated in the UCAPO gala, Dr. GuoLiang Yu, one of the CBA founders received US-China Cooperation Achievement Award
March 10, 2013	Nanjin JianYe District visited CBA-DED office and signed strategic collaboration agreement. Officially appointed CBA to represent Nanjin JianYe District in USA
February 19, 2013	Met with Mr. Feng Ya-Jun, Secretary of Nanjing Jianye District CPC Committee in New York city; and invited the delegation from Nanjing Jianye District to attend and sponsor CBA 2013 Annual Conference in June.
February 2, 2013.	CBA leader engaged Mr. Wang Wenxue, owner of China's Yingfu Enterprise for potential investment in Montgomery County

January 18, 2013	CBA leadership met with Mr. Wang Wenxue, in discussing possible collaboration between CBA and his company.
January 15, 2013	CBA 2012 New Year Gala
January 11, 2013	Meeting with the county DED: CBA input and ideas for DED partnership in China. CBA participation in County Executive's mission trip.
November 4-5, 2012	Visited with the Biopark in Guangzhou for potential collaborations. 在省侨办主任陈仰豪的主导下与生物岛汤总进行深入交流，达成初步合作共识，商谈合作具体条款。
October 19, 2012	Met with EastLinden's Chairwoman Liu Yanhui and VP Dr. Sun from Beijing to discuss the possible collaboration for Chinese Medicine Database applications
October 2, 2012	The 2012 CBA Meeting In conjunction with 8th Annual Conference on Translational Research at University of Maryland School of Medicine: Translational Research, Biopharmaceutics and Personalized Medicine at MSTF Auditorium, 865 West Baltimore Street, Baltimore, MD 21201
2012.9.25-26	CBA delegation visited GanSu LanZhou new economic development zone and presented a speech at Northwest University
Sept. 22-24, 2012	CBA delegation visited ChongQing Lianjiang new development zone.
Sept. 18-21, 2012	CBA delegation attended 2012 Sichuan Oversea High Tech &Talent Meeting and Biomedicine Development Forum 海外高新科技暨高端人才洽谈会及生物医药成果与产业化论坛. Signed Strategic Collaboration Agreement with Sichuan Meishan Economic Development Zone
October 7, 2012	CBA delegation had visited Qingdao Western New Economic Zone and discussed the possibility and date to set up a US office at CBA's Montgomery office.
October 2, 2012	October 2, 2012 CBA Annual Conference in Maryland, Translational Genomics, Biopharmaceuticals and Personalized Medicine, BHI CEO gave a presentation talking about the goals and activities of BHI
August 29, 2012	Introduction of CBA to Elaine Amir, the Executive Director of the Johns Hopkins Montgomery County campus. Potential collaboration

August 27, 2012	Met with LiLi Qi and Tom Street: CBA input and ideas for DED partnership in China. Also explore Tom and Lili's China trip (Sept).
August 25, 2012	Conferred with Mr. Wang Xin from QingDao Overseas Affairs Office to arrange a DED trip to Qingdao to promote business between QingDao and Montgomery County. Also tried to arrange Tom and Lili visit to Qingdao in their September China trip.
August 22, 2012	Met with Rich Bendis, CEO of BioHealth Innovation, discussed CBA's partnership with BHI in attracting investors to its dedicated funds for biohealth commercialization and to develop partnerships in other areas. I see an MOU as a possible outcome for that meeting
July 2-3, 2012	17th CBA Annual Meeting held in Qingdao, China. DBED team lead by Bradley Gillenwater attended the meeting, organized a session introduced the Montgomery bio-incubator projects
June 20, 2012	Hosted a delegation from the Chongqing High Tech Industry Zone led by its deputy director, Mr. Yao Bin. They visited the county biotech community in return to CBA's February visit to Chongqing.
June 17, 2012	CBA and CABA co-organized the first "Biopharma Outlook" reception before the BIO Conference at Boston.
June 12, 2012	Met with Qingdao Municipal Delegation at CBA Headquarters Office in Rockville, Maryland
May 17, 2012	Met with Wuhan National Bio-industry Base (Biolake)
May 10-11, 2012	CBA co-organized and attended Shanghai Bioforum Conference
April 28, 2012	CBA held its Annual Career Development Workshop at Johns Hopkins University Shady Grove Campus, Rockville, Maryland.
March 14, 2012	Met with Sichuan Provincial Delegation in Rockville, Maryland
February 13, 2012	Met with MOST and SFDA delegation from China
February, 2012	CBA delegation visited Taizhou China Medical City and Chongqing.
January 14, 2012	CBA New Year's Gala at Glenview Mansion, Rockville, Maryland
December 1, 2011	Chongqing Municipal Government delegation visited US and held meetings with CBA in Gaithersburg, Baltimore and Potomac, Maryland

October 19, 2011	CBA delegation visited Chongqing, China and held meetings with city municipal government and more than a dozen pharmaceutical companies and universities and signed the CBA-Chongqing Collaborative Framework Agreement.
October 18, 2011	2012 CBA-Chengdu Bioforum, "Translational Medicine: What is happening in China", co-organized by CBA and Sichuan Provincial and Chengdu Governments. More than 50 pharmaceutical companies and institutions attended the meeting.
October, 17, 2011	CBA delegation attended Sichuan 2011 Haike Hui "2011 年海科会" in Chengdu, Sichuan.
October 15, 2011	Co-organized "A Bioforum on International Collaborations in Biomedical Research, Development and Licensing between Research Institutions and Industry" as part of The Second International Medica Expo in Taizhou China Medical City (CMC), Jiangsu.
October 14-15, 2011	CBA delegation attended the Second International Medica Expo in Taizhou China Medical City (CMC), Jiangsu and signed the CBA-CMC Collaborative Framework Agreement.
October 8, 2011	CBA and Chinese Scholars and Students Association (CSSA) held a fun BBQ party for members of both organizations at Centennial Park, Ellicott City, Maryland.
October 2, 2011	CBA Annual Board of Director Meeting, Bethesda, Maryland
September, 2011	Co-organized the Labor Day celebration Black Hill Park, Maryland.
July 26, 2012	Yifan Zhai representing CBA attended the Jiangsu Provincial Conference on Overseas Talents Recruitment held in Nanjin 江苏省人才国际化推进大会
July 22, 2011	CBA delegation attended CMC Healthcare Summit at Waldorf Hotel New York
June 27, 2011	"Bio-Capital Tour" Tour of FDA, United States Pharmacopeia, MedImmune /AstraZeneca, and Human Genome Sciences, co-organized with Montgomery County and Maryland State Department of Business and Economic Development.

June 1-11, 2011	Co-organized and joined Maryland Govenor O' Malley's Asia Mission: Governor's keynote address at the 13th Shanghai BioForum, Biocapital Leadership Luncheon, visited CMC, Tasly and Simcere; further expansion of relationship with Jiangsu MOST
May 19, 2011	Met with CRV Biotech from Shandong China along with Montgomery County Department of Economic Development
May 5, 2011	Annual Career Development Workshop at Johns Hopkins University, Baltimore
April 29, 2011	Visit Suzhou Wuzhong Pharma Industry Base
April 25, 2011	Met with administrative committee of GDD in Guangzhou
March 7, 2011	Met with a delegation of Guangzhou Economic and Technological Development District (GDD) led by Secretary Mr. Lin Weixiang
Feb 20, 2011	Dinner with OCAC delegation
Feb 9, 2011	Lunch meeting with Dr. Tim Shi , CEO of MDGlobo
Jan 20, 2011	Welcome President Hu Jintao of China during His Official State Visit to USA, Washington DC
Jan 8, 2011	Chinese New Year Gala in Glenmont Mansion, Rockville
Dec 3, 2010	Met with Mr. Zhu Yan, Director-General of Beijing Municipal Commission of Economy and Information Technology and toured MedImmune and HGSI
Dec 2, 2010	Met Suzhou delegation led by Mr. Weiyue Lu, Vice Secretary General of the People's Government of Suzhou along with Montgomery County Department of Economic Development
Nov 23, 2010	Overseas Talents Recruitment Symposium for Yunnan delegation in Virginia
Nov 17, 2010	Co-hosted a welcome reception with BIO for the China Pharmaceutical Industry Research & Development Association (Sino-PHRDA) delegation with 30 top executives from 17 Large Chinese Pharma Companies, Rockville, Maryland
Nov 17, 2010	Reception for 36 Chinese Entrepreneurs, Rockville, Maryland

Oct 18, 2010	Suzhou Wuzhong Talents, Projects & Investors Partnership Conference
Oct 2, 2010	Board of Directors and Executive Committee Leadership Retreat, Bethesda
Sept. 20, 2010	Delegation from Tongji Medical College (同济医学院) of Huazhong University of Science and Technology (华中科技大学), Maryland.
Sept 16, 2010	10th Overseas Entrepreneur Partnering Conference (Hua Chuang Hui), Wuhan , China
Sept 15, 2010	4rd OCAC Conference for the presidents from Overseas Professional Associations, Wuhan, China
Sept 11, 2010	UCAPO picnic to show support for our alliance partners
Sept 2, 2010	Meeting with SFDA delegation from Wuhan, China
Aug 16, 2010	Overseas Talents Recruitment Symposium for the Su-Tong Science & Technology Park delegation
June 30, 2010	Reception for the visitors from the JINING in Shandong, Rockville
June 22, 2010	Jiangsu-Maryland Biopharmaceutical Forum in Maryland
June 18, 2010	Co-organizing 中关村管委会副主任周云帆的创业中关村报告会
June 14, 2010	2010 Tri-Yangtze River Conference for the presidents from Overseas Professional Associations, Hangzhou, Jiangyi, Shanghai China
May 30, 2010	Meeting with Science and Technology Division of Beijing City Government
May 27, 2010	Meeting with Wuxi Delegation, College Park, Maryland
May 25, 2010	Meeting with Beijing delegation, Maryland
May 4, 2010	China Events at 2010 BIO International Convention, Chicago
May 1, 2010	CBA Workshop on NIH Grant Application, Rockville, Maryland
April 23, 2010	SEED Final Competition and Award Ceremony, Shanghai, China
April 17, 2010	Welcome Gala for Mr. Zhang Yesui, the ninth Chinese ambassador to the US, Rockville, Maryland
April 5, 2010	China 2010 Pharma R&D Summit, Shanghai, China

April 4, 2010	Met with a delegation from Qingdao, Maryland
April 1, 2010	Met with Wuxi Huishan delegation, Rockville, Maryland
March 20, 2010	2010 CBA Career Development Workshop, Rockville, Maryland
March 10, 2010	CBA meeting at the Chinese Embassy, Washington, DC
February 21, 2010	2010 CBA Chinese New Year Gala, Glenview Mansion, Maryland
February 15, 2010	Farewell banquet for Mr. Zhou Wenzhong, the eighth Chinese ambassador to the US, Arlington, Virginia
February 2, 2010	CBA President Yifan Zhai met with the people at the Guangdong provincial MOST, Guangzhou, China
January 28, 2010	CBA President attend 10th Guangdong Provincial People's Political Consultative Conference, Guangzhou, China
January 16, 2010	CBA president Dr. Yifan Zhai attended the opening ceremony of the University of Maryland-China Research Park
January 15, 2010	Dinner Meeting with Delegation from China Medicine City, Rockville, Maryland
January, 6, 2010	SEED Kickoff Meeting, Guangzhou, China

Chinese Biopharmaceutical Association – USA (CBA)

Membership Application (or Renewal) Form

Go to Online Member Registration for joining CBA.

Two payment methods are available: Online Pay Pal, or send the completed application form with a personal check payable to CBA to the address: CBA-USA, P.O. Box 61362, Potomac, MD 20859-1362.
Contact Dr. Richard Y. Zhao at 410-706-6301 or email rzhao@som.umaryland.edu with Membership questions.

Name (English) (First) _____ (MI) ___ (Last) _____

Name (Chinese)_____ Degree(s) _____ Degree Pursuing_____

Telephone (_____)_____-_____ Fax (_____)_____-_____

E-mail Address (1)_____ (2)_____

Title or Position_____ Department or Division_____

Institute, Agency or Company_____

Mailing Address_____

City_____ State_____ ZIP_____

Fees:

1. Check one desired category of your membership:

____	**Regular Member**	**$30.00**
____	**Postdoctoral Member**	**$20.00**
____	**Student Member**	**$10.00**
____	**Member in China**	**$20.00**

Total Payment (please make check payable to "CBA-USA"): $_____

(Multiple year's membership discount: 5% for two years, 10 % for three years or more)

Grand Total Payment: Total Payment X 2 (for two years membership) X 95% $_____

Total Payment X __ (for >two years membership) X90% $_____

(Please save this receipt)

Today's Date: _____/____/_____

Notes

Notes